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Summary 
Glioblastoma multiforme (GBM) constitute over 50 % of primary brain tumors in adults. The 
tumor is heterogeneous and highly infiltrative. Its nature makes it extremely aggressive and 
incurable. Thus, today’s treatment modalities only have a palliative function and provide a 
modest survival benefit. This states the need for further research to reveal the biological 
mechanisms behind GBM development. 
 
The name glioblastoma multiforme reflects the expression of markers of many different CNS 
cell lineages in this tumor. Notably, GBMs have been reported to comprise cells that express 
stem cell markers, and it is postulated that glioma stem cells is the cell type initiating and 
maintaining this tumor. Also, several lines of evidence strongly suggest that hypoxia is a 
cancer stem cell niche. Furthermore, hypoxia is associated with poor prognosis in many solid 
cancers, being implicated in induction of radio- and chemoresistance and in tumor invasion. 
Hence, hypoxia and cancer stem cells may be two factors that contribute to the failure to treat 
this tumor. They might therefore be candidates which can be targeted in new therapeutical 
strategies for GBM. 
 
To assess the expression of cancer stem cell markers in hypoxia, five glioma cell lines were 
cultured for various time periods in normoxic (21 %) and hypoxic (0.5 and 2 %) conditions. 
Expression of a panel of cell lineage markers was investigated in the different oxygen 
conditions. Additionally, cell behavior in hypoxia compared to normoxia was evaluated by 
investigating proliferation, migration and apoptosis. 
 
We found that none of the stem cell markers that we looked at were upregulated in hypoxia, 
which is contradictory to previous reports. Instead, these stem cell markers and the astrocytic 
marker GFAP were all downregulated. Furthermore, cell proliferation and migration both 
decreased in hypoxia. This points at an overall slow down of the glioma cell machinery in 
hypoxia.  
 
Other studies have mainly been performed on small selections of biopsy material cultured in 
serum free medium, and this approach should be included in the present study in the future. 
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1 Introduction 
1.1 Cancer 
Caused by successive malignant changes – mutations – in the DNA of one cell, cancer is a 
disease of the genome rather than of an organ. Still, the disease manifests as an abnormal 
proliferating mass in the body part where the transformed cell originates. The cancer cells 
acquire the abilities to invade surrounding tissue, metastasize and eventually kill the patient as 
an extensive disease affecting multiple organs. Research over the last decades has advanced 
our understanding of many aspects of cancer, and dramatically improved the prognosis for 
some cancer types. However, basic mechanisms mediating tumor initiation and progression 
are still incompletely understood. Thus, despite immense amounts of money and man hours 
spent on research the last decades, cancer still stands out as a major cause of death and 
morbidity, causing approximately 13% of all deaths
1
 globally.  
 
1.1.1 Cancer development 
A review published in Cell by Hanahan and Weinberg (2000) sums up the current 
understanding of cancer. Hanahan and Weinberg introduced the well known concept The Six 
Hallmarks of Cancer. The hallmarks can be explained as a set of abilities that a cell must 
acquire in order to transform into a malignant cancer cell: the cell has gained the ability of 
unlimited division; it has become insensitive to anti-growth factors; it is self-sufficient in 
growth signals; it is resistant to apoptotic signals; it can promote angiogenesis and it can 
invade other tissues and metastasize
2
. Over the past decade the understanding of tumor 
biology has evolved, which has revealed the need of further cancer hallmarks. Recently, 
Hanahan and Weinberg published an updated version of their Hallmarks
3
. Emphasized is the 
cancer cell’s capability to manipulate its stroma to create an advantageous microenvironment. 
Two enabling characteristics have been added; a prerequisite for evolution of the hallmarks, 
namely genomic instability, and tumor promoting inflammation. Additionally, a pair of new 
hallmarks have been suggested, the ability to avoid immune destruction and to deregulate 
metabolism in order to sustain continued growth
3
. 
 
Cancer is caused by abnormal changes in the DNA, and several changes are required for 
transformation of a normal cell into a cancer cell. Thus, cancer cells acquire several different 
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mutations, and cells that harbor mutations which confer a growth advantage are selected. This 
way, tumors evolve in a clonal manner arising from a single mutated cell
4
. Although, the very 
first genetic lesions that lead to development of a tumor may be inherited, most people that 
are diagnosed with cancer accumulate the mutations throughout their lives. Mutations may 
arise spontaneously or may be caused by environmental factors. In either case they may arise 
in what is called tumor suppressor genes and oncogenes. Oncogenes are genes that encode 
proteins that promote cell growth and division. Mutations cause an oncogene to be 
overexpressed or their gene products are rendered overactive. The gene may for example 
encode a growth factor or a component within a mitotic signaling cascade inside the cell. 
With overexpression or over-activity of the protein, the mutated gene promotes cell growth 
and division stronger than normal
5
. Oncogenic mutations are dominant, which means that 
only one allele needs to become mutated in order to influence cancer develoment
5
. Tumor 
suppressor genes on the other hand encode proteins that inhibit cell cycle progression, or they 
encode proteins promoting apoptosis in case of deleterious stress to the cell
5
. A well known 
tumor suppressor is p53, which is mutated in over 50 % of all cancers. p53 induces apoptosis 
in case of irreparably damaged DNA
6
. Both alleles of a tumor suppressor gene have to 
become mutated in order to influence cancer development, hence mutations in tumor 
suppressor genes are recessive mutations
5
. There are two main consequences of activated 
oncogenes or inactivated tumor suppressor genes; first, the proofreading machinery that 
normally prevents a damaged cell from dividing is not working and the signaling pathways 
mediating programmed cell death are disrupted. Secondly, the cell achieves stronger mitotic 
signals and divides faster than normal. This leads to increasing genomic instability, additional 
mutations and uncontrolled development of an abnormal cell mass. 
 
All cells must be in vicinity to blood vessels in order to both receive nutrients, growth factors 
and oxygen, and to dispose waste products from their metabolism. This applies for tumor cells 
as well. When the tumor reaches a certain size, the increasing cell mass outgrows its blood 
vessel supply
7
. As a survival response tumor cells promote angiogenesis, the sprouting of new 
blood vessels from existing ones. This is mediated by secretion of vascular endothelial growth 
factor (VEGF) that is the major inducer of angiogenesis. VEGF is upregulated in response to 
both hypoxia and different growth factors
8
. VEGF induces destabilization of existing vessels, 
proliferation, migration and survival of endothelial cells that subsequently form new blood 
vessels
5, 8
. Cancer cells also release various other signaling molecules with a broad range of 
biological effects on the microenvironment, including remodeling of the extracellular matrix 
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and the tumor vasculature
5
. Since tumor cells almost exclusively escape their primary site 
through the blood or lymphatic system, angiogenesis is a key event in cancer cell metastasis. 
Since most cancer related deaths result from metastasis, angiogenesis is also coupled to 
overall tumor aggressiveness
9
. The metastatic process starts with migration of cancer cells 
from the primary site to a blood vessel, where the cells intravasate into the blood circulation. 
Cells are transported with the blood flow and eventually they get trapped in another body part, 
either by size restriction or by specific interactions
9
. Here, cells may extravasate and colonize 
surrounding tissue to form a secondary tumor, a metastasis
5, 9
. The whole process depends on 
a range of factors, including the ability to evade immune destruction, altered expression of 
cell adhesion molecules, as well as activation of enzymes that break down the extracellular 
constituents that restrain cells to one place
9
. Moreover, when the metastasizing cancer cells 
reach their final destination, the microenvironment must be permissive to sustain growth of 
the cancer cells. As reviewed by Ribatti et al, this is known as the “seed and soil theory” 
already proposed by Stephen Paget in 1889, and explains why certain cancers tend to spread 
to specific organs
10
.  
 
1.2 Brain Cancer 
Cancers of the central nervous system (CNS) are classified according to their resemblance 
with the main cell types of the CNS. Thus, gliomas are similar to glial cells of the brain and 
can be subdivided into oligodendrogliomas, ependymomas and astrocytomas
11
. Astrocytomas 
are the most common brain cancers, and together with other CNS tumors, astrocytomas are 
given WHO grades I-IV corresponding to malignancy. This grading is based on histological 
criteria such as mitotic activity, anaplasia, nuclear atypia, microvascular proliferation and 
presence of pseudopalisading necrosis
11
. Tumor grade correlates with prognostic outcome, 
and provides the basis for deciding treatment regimen
11
. 
 
1.2.1 Glioblastoma multiforme  
Each year about 19,000 persons are diagnosed with malignant primary brain tumor in the 
United States
12
. Of these, Glioblastoma multiforme (GBM) constitutes over 50 % of the cases, 
which makes it the most common primary brain tumor. Radical surgery is impossible due to 
its highly infiltrative growth and radio- and chemotherapy have a limited effect. Thus, the 
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prognosis for GBM patients is extremely poor, with a median survival time of about 14 
months
13
, and almost 100 % mortality rates. 
 
Ionizing radiation is the only established risk factor for primary brain tumors. In addition Li-
Fraumeni syndrome, Turcot syndrome, tuberous sclerosis and neurofibromatosis are 
associated with an increased risk of developing GBM as well as other cancer types
14
. 
Epidemiological data also suggest that there exists a non-syndromal genetic predisposition to 
GBM, but the genetic basis for this is not known
14
. As such, people of Caucasian origin are 
diagnosed more often with GBM. Also, men have a higher prevalence than women (3:1), and 
the incidence rate increases with age. Still, the possible risk factors account for a small part of 
the cases only (reviewed in
15
). 
 
Table 1.2.1: Astrocytic tumors graded according to the WHO system described above
11
. 
 
1.2.2 Mutations in GBM 
Although there is no unifying genetic signature common to all GBMs, they are still 
characterized by certain patterns of mutations which are present in varying proportions of 
GBMs. The Cancer Genome Atlas Research Network has combined data from a multi-domain 
analysis of 206 glioblastomas. Their compilation of data on copy number alterations, 
abundance of coding genes and non-coding microRNAs and single nucleotide polymorphisms 
has revealed three signaling networks that are frequently altered in GBMs: the 
RTK/RAS/PI(3)K (88%), p53 (87%) and RB (78%) pathways
16
.   
 
Astrocytic 
tumor 
Grading Criteria 
Pilocytic 
Astrocytoma 
I 
Low proliferative potential, possible curable by surgical 
resection only. 
Diffuse 
Astrocytoma 
II 
Infiltrative, low level of proliferation, nuclear atypia. Tend to 
recur as higher grade glioma.  
Anaplastic 
Astrocytoma 
III Infiltrative, mitotic activity, nuclear atypia, anaplasia. 
Glioblastoma 
Multiforme 
IV 
Highly infiltrative, and in addition to grade III criteria: 
microvascular proliferation, necrotic areas, pseudopalisades. 
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GBM can arise de novo or as a malignant progression from lower grade astrocytic tumors
17
. 
These are called primary and secondary GBM, respectively. Primary GBM is the most 
frequent variant and is more common among elderly GBM-patients. Secondary GBM occurs 
more often in younger patients
17
. Even though the two GBM variants have the same 
histological appearance, the chromosomal aberrations that characterize the two types of GBM 
are somewhat different (reviewed in
18
), as listed in table 1.2.2. 
 
Table 1.2.2: Characteristic chromosomal aberrations found in primary and secondary GBMs. The 
percentage of GBMs harboring each mutation is indicated in brackets. Adapted from Ohgaki and 
Kleihues
18
. 
Astrocytic tumor 
Astrocyte or precursor stem cell 
Development of primary 
GBM 
Development of secondary 
GBM  
Low grade astrocytoma 
(grade II) 
no clinical manifestation 
TP53 mutation 
(59%) 
Anaplastic astrocytoma 
(grade III) 
no clinical manifestation 
TP53 mutation 
(53%) 
GBM 
(grade IV) 
RB methylation (14%) 
LOH 22q (41%) 
LOH 19q (6%) 
LOH 10q (70%) 
LOH 10p (47%) 
EGFR amplification (40%) 
EGFR overexpression (60%) 
P16INK4a deletion (31%) 
p14
ARF 
(76%) 
TP53 mutation (28%) 
PTEN mutation (25%) 
RB methylation (43%) 
LOH 22q (82%) 
LOH 19q (54%) 
LOH 10q (63%) 
LOH 10p (8%) 
EGFR amplification (8%) 
EGFR overexpression (10%) 
P16INK4a deletion (19%) 
p14
ARF 
(76%) 
TP53 mutation (65%) 
PTEN mutation (4%) 
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1.3 Hypoxia 
Hypo- is a prefix from the Ancient Greek language and means under, while -oxia comes from 
oxygen, hence hypoxia means low oxygen. The physiological oxygen concentration in adults 
varies with tissue and even in regions of the same organ
19
, but the average body oxygen 
concentration is around 3 %
20
. Oxygen levels below the physiological concentration are 
considered being hypoxic, and brain tumor hypoxia is defined to be between 0.1 and 2.5 %
21
. 
Hypoxia triggers necessary physiological responses such as wound healing. Several 
pathological conditions may lead to tissue hypoxia, for example embolism, thrombosis, 
environmental factors and tumor growth
22
. Hypoxia has a profound effect on all oxygen 
utilizing cells, and processes such as apoptosis, cell signaling, metabolism and cell cycle 
progression are all regulated in response to hypoxia
23
. In response to a hypoxic state, cells can 
be damaged and die, or they may adapt to scarcer conditions
24
. 
 
Although several isoforms have been found
25
, the most studied transcription factor 
responsible for an hypoxic response is hypoxia inducible factor 1 (HIF-1)
23
. HIF-1 is a 
heterodimer consisting of two basic helix-loop-helix (bHLH)/PAS (Per Arnt Sim) monomers 
named HIF-1α and ARNT (aryl hydrocarbon receptor nuclear translocator)26. ARNT is also 
known as HIF-1β26, 27.  
 
 
Figure 1.3.1: Schematic overview of HIF-1α and ARNT monomers. bHLH/PAS 
domains constitute the dimerization surface where the monomers contact each 
other. bHLHs also make up the DNA-binding structures of HIF. ODDDs 
(oxygen dependent degradation domains) are targeted by prolyl hydroxylase. N-
TADs and C-TADs (transcriptional-activation domains) interact with 
transcriptional co-activators, and C-TAD is also negatively regulated by 
hydroxylation. Adapted from Brahimi-Horn  and Pouyssegur
25
.  
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Table 1.3.1: bHLH/PAS proteins and isoforms involved in the hypoxic response 
Protein Function 
HIF-1α 
Both are activated in response to hypoxia, but have different target genes
25
 
HIF-2α 
HIF-3α Negative regulator of HIF-1α and HIF-2α25 
ARNT 
(HIF-1β) 
Not oxygen-regulated, dimerizes with HIF-1 and -2α subunits (and other 
nuclear receptors
28
) to form the active transcription factor 
ARNT2 
(HIF-2β) 
Less investigated, exact function not known
28
  
 
 
Figure 1.3.2: (A) When physiological oxygen levels are present, prolyl hydroxylation and asparginyl 
hydroxylation of HIF-1α is catalyzed by prolyl 4-hydroxylase (PHD) and factor inhibiting HIF (FIH). (B) 
Asparginyl hydroxylation inhibits HIF-1α from interaction with the transcriptional co-activators CBP and 
p300. Prolyl hydroxylation allows the von Hippel-Lindau tumor suppressor (VHL), an E3-ligase, to 
interact with and poly-ubiquitinate HIF-1α. (C) Ubiquitination targets HIF-1α for degradation in the 
proteasomal pathway (D). (E) When oxygen is not available, PHD and FIH are inhibited, thus HIF-1α is 
stabilized (F) and translocates to the nucleus. (G) Here, HIF-1α heterodimerizes with ARNT. HIF-1 is now 
a functional transcription factor that binds to HREs and activates transcription
25
. 
 
Under normoxic conditions, the constitutively expressed HIF-1α is located in the cytoplasm. 
Here, HIF-1α is continuously degraded through the proteasomal pathway (Shown in figure 
1.3.2 A-D). In lack of oxygen, unhydroxylated HIF-1α reveals its nuclear localization signal 
(NLS) and is translocated to the nucleus where it heterodimerizes with ARNT
23
. HIF-1 targets 
promoters with the sequence 5’ – RCGTG – 3’ (R=A/G), which is called the hypoxia 
responsive element (HRE)
25, 27
. As reviewed by Semenza (2003), more than 60 genes 
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involved in such various functions as cell proliferation, motility, apoptosis, morphology and 
metabolism are found to be regulated in response to hypoxia
29
. Furthermore Iyer et al 
demonstrated that in mice, HIF-1α -/- embryos died within embryonic day 10.530. This 
underscores the extensive importance of this transcription factor in development and 
throughout life.  
 
Table 1.3.2 A selection of proteins encoded by hypoxia-activated genes (modified from Fandrey
31
). 
Protein Function 
Erythropoietin (EPO) 
Increases production of red blood cells in the bone 
marrow
31, 32
 
Glucose transporter 1 (GLUT1) Transports glucose into the cell
31, 33
 
Phosphofructokinase (PFK) 
Key regulator in the glycolytic pathway, 
(phosphorylates glucose-6-phosphate)
31, 34
 
Enolase 
Glycolytic enzyme (2-phosphoglycerate to 
phosphoenolpyruvate)
31, 34
 
Vascular endothelial growth 
factor (VEGF) 
Stimulates vasculogenesis and angiogenesis
31, 35
 
 
1.3.1 The role of hypoxia in cancer 
When tumors grow beyond 1-2 mm in diameter, they outgrow the distance by which oxygen 
can diffuse into the tumor center from nearby vessels
36
. In addition, tumor neovasculature is 
highly aberrant and inefficient in delivering oxygen and nutrients to surrounding cells
37
. 
Hence, the core of the tumor mass will become hypoxic. This can lead to apoptosis and 
necrosis, as some tumor cells lack the ability to adapt to the harsher conditions of the hypoxic 
area. A portion of cells may have acquired mutations in pro-apoptotic genes such as p53, 
which favor their survival despite hypoxic environments
24, 38
. Tumor cells upregulate genes 
associated with survival programs. For instance, VEGF is secreted and the number of 
glycolytic enzymes are increased (reviewed by Fandrey
31
). The master regulator responsible 
for these compensatory gene expression changes is HIF-1
23, 39
. 
 
Tumor hypoxia has long been recognized as a poor prognostic factor, and already more than 
half a century ago physicist Louis Harold Gray suggested that there was a connection between 
tissue oxygen concentration and response to irradiation
40
. Radiation creates reactive oxygen 
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species (ROS) through two mechanisms; either by radiolysis of water molecules which again 
react with DNA, or by directly ionizing DNA. In both instances, a free radical is created in the 
DNA molecule
5
. In an oxygenated tumor the radical can react further with O2 and give a fixed 
damage in the cell’s DNA (figure 1.3.1.1). Radiation induced damage is therefore dependent 
on the presence of oxygen in the tissue.  In hypoxic areas of a tumor, free radicals will not be 
created in sufficient amounts for radiation therapy to be fully effective. Notably, the direct 
ionization of DNA is reversible in lack of oxygen
41
.  
 
Figure 1.3.1.1: Direct action of irradiation on DNA. In presence of oxygen the reaction proceeds 
through oxidation to the more stable forms DNA-OO· and DNA-OOH, which causes permanent 
damage to DNA and induces cell death. In absence of oxygen, the first step where DNA· is 
formed is reversible, and there is no permanent change to DNA. A blue arrow indicates the 
favored reaction in each condition. Modified from De Ridder et al
41
.  
 
Furthermore, cancer cells have other strategies to protect themselves against ROS-induced 
cell death. As mentioned above, rising HIF-1α levels induce genes which enable the cells to 
cope with lower oxygen and nutrient levels
31
. In addition, since hypoxia acts as a selection 
pressure for cells resistant to apoptosis, the cells that are selected will also be resistant to 
radiotherapy that induces apoptosis by causing DNA damage
24, 36, 38
. In healthy cells, damage 
from ROS-production causes cell cycle arrest and DNA repair if the lesion is mild. In case of 
irreparable damage, the p53 pathway induces apoptosis
42
. In tumor cells however, loss of cell 
cycle control and disruption of apoptotic pathways allow for progression through the cell 
cycle, even in the presence of extensive DNA changes
38
. 
 
Additionally, tumor cells display increased levels of antioxidant production, which represents 
an additional defense mechanism against ROS. High levels of antioxidants will quench ROS 
before they are allowed to react with the DNA, causing further damage
43
. As previously 
reported by Schwartz et al., hypoxia may also mediate resistance to irradiation by another 
more indirect mechanism. Even though an area is not hypoxic at the time radiation is given, it 
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may become hypoxic in response to radiation. After radiation treatment, tumor vasculature 
function is disrupted; hence the irradiated area develops hypoxia. HIF-1 induced transcription 
follows, and may play a role in helping tumor cells survive damage to the microenvironment 
caused by radiation
44
.  
 
The hypoxic selection of cells resistant to apoptosis also mediates resistance to chemotherapy. 
Moreover, hypoxia has been shown to upregulate expression of the multidrug resistance 
ABC-transporter P-glycoprotein (MDR1)
45
. This transmembrane channel transports different 
xenobiotics out of the cell, including chemotherapeutic drugs
46
. Moreover, Brown et al 
emphasized the significance of the longer distance between blood vessels and hypoxic cells 
compared to normoxic cells. Due to this difference hypoxic cells may be less exposed to 
intravenously administered cytotoxic agents than normoxic cells. In addition, hypoxic cells 
tend to divide slower, and they are therefore less influenced by chemotherapy, which 
principally act on rapidly dividing cells
36
.  
 
Probably, none of these factors alone can explain resistance to apoptosis inducing therapies 
such as radiation. Most likely a hypoxic environment that selects for apoptosis resistant 
cancer cells combined with the versatile ability to withstand ROS effects on DNA enables 
cancer cells to survive radiation therapy.  
 
1.3.2 Hypoxia in brain tumors is associated with a more aggressive 
phenotype 
Glioblastoma Multiforme is characterized by florid angiogenesis and highly infiltrative 
growth. As reviewed by Rong et al (2006), the characteristics that distinguish high grade from 
low grade gliomas are the presence of pseudopalisading necrotic foci and microvascular 
hyperplasia
47
. Necrotic areas are anoxic, and palisading cells at the rim of these necrotic foci 
will receive slightly more oxygen and become hypoxic. The consequence is VEGF 
upregulation and hypoxia-driven angiogenesis in proximity to necrotic areas
47
. Thus, hypoxia 
and angiogenesis are key events in brain tumor progression. 
 
Notably, several lines of evidence strongly suggest that hypoxia promotes invasive growth as 
well. Histological examinations reveal that cells in the palisading region are migrating 
outwards and away from the necrotic region
47, 48
. Also, matrix metalloproteinase-2 (MMP-2) 
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is found to be upregulated, which is associated with migratory behavior
48, 49
. Pennacchietti et 
al also reported that c-Met tyrosine kinase, a high affinity receptor for the pro-invasive 
cytokine HGF, is induced by hypoxia and is upregulated in hypoxic areas of human tumors
50
. 
Furthermore they demonstrated that hypoxia amplified hepatocyte growth factor (HGF) 
signaling and increased tumor invasion. Hypoxia therefore seems to induce migratory 
properties in astrocytoma cells, which may account for the ability of GBM to expand and 
spread throughout the brain so rapidly
47
. Thus, both angiogenesis and glioma cell invasion, 
which contribute to the aggressive phenotype of brain tumors, are regulated by hypoxia.  
 
 
Figure 1.3.2: Schematic drawing of pseudopalisading necrosis. Central in the 
tumor lays foci of necrotic cells around a regressing vessel (black 
arrowhead). The vessel is obstructed by a clot (black arrow). Surrounding, 
hypoxic cells are migrating away from the central necrosis, causing a rim of 
denser cell layers that resemble palisading tissue, wherefrom the name 
pseudopalisading comes (white arrowhead). Microvascular proliferation 
(white arrow) is induced by VEGF-secreting hypoxic cells. Adapted 
from
51
(review). 
 
As previously mentioned, the traditional view is that expanding tumors outgrow their vascular 
supply and that hypoxia and tumor necroses arise in cells furthest from the vasculature. 
Another theory applicable to GBMs is that the regression of clotted and necrotic vessels 
caused by thrombosis leads to necrotic regions with outwardly migrating cells
52
. This is 
supported by the fact that thrombosed vessels are found in virtually all GBMs
48
. An important 
factor contributing to thrombosis in GBMs is the tissue factor (TF)
52
. TF is normally 
expressed in perivascular cells, and exists both as a transmembrane receptor and in a soluble 
form. TF is activated when contacting its ligand, which is only present in blood plasma. 
Through a series of events this receptor-ligand complex leads to formation of a blood clot
52
. 
With the aberrant and leaky vasculature of a tumor, TF will easily bind its ligand and lead to 
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thrombosis. The TF-gene is controlled by several hypoxia driven promoters, which further 
states the role of TF mediated thrombosis and in GBM hypoxia and necrosis
47, 53
. Moreover, 
the strongly expressed VEGF cause upregulation of both tissue plasminogen activator (tPA) 
and its inhibitor plasminogen activator inhibitor (PAI-1). By generating plasmin, tPA 
normally breaks down blood clots. PAI-1 is inhibiting this action, which results in lower 
fibrinolytic activity, further contributing to the prothrombotic status of GBM patients
54
. 
 
1.3.3 Hypoxia, cancer and cancer stem cells 
As reviewed by Reya et al stem cells are defined as cells that have the ability of infinite self-
renewal, giving rise to identical cells that maintain their undifferentiated state (symmetrical 
division). At the same time, they are multipotent and capable of giving rise to the specialized 
cells that make up and organ (asymmetrical division)
55
. Both stem cells and cancer cells have 
the ability of indefinite division, which gave rise to the theory that there is a “cancer stem 
cell” (CSC) responsible for the formation and growth of tumors55. The bulk of evidence for 
existing CSCs are found in acute myeloid leukemia
55
, and a debate has been going on for 
many years whether CSCs or stem like cells exist for solid tumors. On one side is the 
hypothesis that essentially all cells of the heterogeneous tumor have the same ability of 
unlimited self-renewal and contribute equally to tumor growth and progression
56
. On the other 
side is the theory which implies that a small population of CSCs sustains the tumor by 
undergoing asymmetric division. In brain tumors, these cells may arise from transformed 
neural stem cells, or by dedifferentiation of transformed mature cells. Independent of which 
cell type they arise from, undergoing asymmetrical division is thought to preserve their stem 
like character while populating the tumor with more differentiated cells with limited 
proliferative potential
55
. Importantly the current treatment failures for many cancer types, 
including GBMs, have been attributed to the presence of CSCs. Based on the increased ability 
of normal stem cells to resist chemotherapy, these CSCs may be implicated in drug 
resistance
57, 58
. Thus, cancer drugs will have to target CSCs specifically, and not only their 
more differentiated progeny. Otherwise CSCs will re-populate the tumor after the treatment is 
stopped
9
.  
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Figure 1.3.3: The cancer stem cell hypothesis and its therapeutic implications. Tumors are 
hierarchically organized: CSCs have the ability to self-renew as well as reconstitute all the 
different tumor cell types through differentiation (left panel). If the CSC pool is successfully 
eradicated through targeted therapies, the remaining cells will be unable to cause a tumor 
relapse. However, incomplete depletion of the CSC pool will inevitably be followed by tumor 
recurrence due to CSC self-renewal (right panel).  
 
Hypoxia preserves the dedifferentiated state of normal neural stem cells and influences cell 
fate, while 20 % oxygen promotes differentiation
59, 60
. Thus hypoxia may play a similar role 
in solid tumors, by creating a niche for CSCs in which they are maintained in an 
undifferentiated state. Several groups have reported an increased fraction of cells expressing 
stem cell markers such as CD133 (Prominin-1) when different brain tumor cells are cultured 
in hypoxia
61-63
. Furthermore, co-expression of HIF-2α and CD133 has been reported61, 
implicating HIF-2α as a transcription factor mediating survival, self-renewal and stemness in 
a hypoxic environment. Among transcriptional targets of HIF-2α are the genes OCT4 and 
SERPINB9
64
. The Oct-4 protein is itself a transcription factor and is associated with self-
renewal
64
. SerpinB9 is a protease inhibitor linked to mediating immune evasion of CSCs
65
. In 
addition, HIF-2α seems to be active in glioma stem cells but not in “normal” glioma cells or 
brain progenitor cells
61, 66
, suggesting that HIF-2α is regulating gene expression specifically in 
glioma stem cells. Overexpression of HIF-1α did not increase expression of typical stem cell 
markers, while overexpression of HIF-2α resulted in upregulation of stem cell markers such 
as CD133, Oct-4, and a component of the Notch pathway, MAML3 (Seidel et al). Moreover, 
Li et al performed immunohistochemistry on glioblastoma biopsy specimens and showed 
expression of HIF-2α and CD133 in a few cells around necrotic areas, while the majority of 
tumor cells expressed HIF-1α61, suggesting that HIF-2α is a marker of glioma stem cells.  
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Together, these findings establish hypoxic areas within tumors as the microenvironmental 
niche that sustains CSCs. Since HIF-2α expression is restricted to the subpopulation of glioma 
stem cells it may provide a target by which therapy can be directed against the tumor 
initiating cells
61
.  
 
1.4 Therapy 
1.4.1 Conventional therapies for Glioblastoma Multiforme 
Although there is a multimodal treatment regiment in use for GBM patients, it is mainly 
palliative and provide only modest survival benefit
67
. This is due to the highly infiltrative 
nature of the tumor, which makes radical surgery impossible
67
. Symptoms are mainly caused 
by intracranial pressure due to the mass effect of the tumor and the surrounding edema or by 
destruction of functional brain tissue due to tumor invasion. Symptoms of increased 
intracranial pressure include headaches, nausea and drowsiness, while tumor invasion may 
cause personality changes, paresis and epileptic seizures, depending on the location. 
Therefore, corticosteroids and antiepileptic drugs are often administered until surgery has 
been performed
68
. In addition to surgery, radiation therapy (total dose 60-65 Gy) with 
concomitant and adjuvant chemotherapy is routinely given, as Stupp et al (2005) reported that 
a combination of radio- and chemotherapy with the alkylating agent Temozolomide (TMZ) 
increases overall survival with approximately two and a half months
13, 68
 compared to 
radiotherapy alone. 
 
1.4.2 New approaches to treatment 
A huge number of clinical trials for testing drugs that potentially act against GBM are 
currently ongoing. Some compounds that target deregulated pathways have been FDA-
approved for treatment of GBM as well. Since GBMs are highly vascular tumors, they may be 
attractive candidates for anti-angiogenic therapies. The VEGF inhibitor Bevacizumab/Avastin 
(bev) was FDA-approved for GBM treatment in 2009
69
. Bev is a recombinant humanized 
antibody directed against secreted VEGF, hence bev targets angiogenesis indirectly. 
However, despite a high initial response rate to bev, there seems to be no overall improved 
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survival, and even a rapid clinical decline after treatment has been terminated
70
.  Notably, bev 
has been associated with increased invasion
71
. 
 
Epidermal growth factor receptor (EGFR) activity or abundance is commonly altered in 
GBMs, and small molecules and antibodies targeting the EGF-receptor have been extensively 
studied. Erlotinib/Tarceva is a small molecule inhibitor targeting EGFR, which has been 
validated in clinical trials enrolling GBM patients, but it has not prolonged survival
72
. Since 
aiming at EGFR alone does not show promising results, attempts are made to simultaneously 
target downstream proteins in the EGFR-signaling cascade, such as the mammalian target of 
rapamycin (mTOR). Several mTOR inhibitors such as rapamycin, temsirolimus, everolimus 
and deforolimus have been tested in trials as single or combinatorial drugs, but so far the 
clinical responses have been poor
73
. 
 
The fact that these treatments largely fail to improve patient outcome underscores the need of 
translational research and new clinical trials in order to develop new and more effective 
treatments for GBM.  
 
1.4.3 Targeting hypoxic cells  
As previously mentioned hypoxia has been associated with poor prognosis in many solid 
cancers, and insufficient oxygen levels in the tumor bed at the time when radiation is given 
strongly influences the response to radiotherapy
40, 74
. Attempts have been made to resensitize 
hypoxic tumors to radiation by different approaches, but so far none have been accessible and 
effective enough to become routine practice in the clinic
75
. One of the first strategies to 
modify the hypoxic microenvironment of tumors was hyperbaric breathing of oxygen, 
normally at 3 atmospheres, to increase the overall oxygen pressure in the blood
75
.  
Nitroimidazoles are also assessed because they mimic oxygen in the chemical process where 
radiation leads to creation of free radicals
75
. Hypoxic cytotoxins that act by specifically 
destroying hypoxic cells rather than sensitizing cells to radiation
75
, have also been tested. 
Other approaches include targeting HIF-1 with small molecule inhibitors to prevent the whole 
angiogenic and survival program induced by this transcription factor in hypoxic cells. 
Compounds have been found which in cell-based systems inhibit HIF-1α protein synthesis, 
influence protein stability, reduce interactions with co-activators and ARNT or prevent 
binding to DNA
76
. Still, targeting hypoxia and HIFs stand out as an approach that is 
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extensively studied in the laboratories, but repeatedly fails translation into the clinic
75
. Testing 
of small molecular inhibitors in animal models and clinical trials will reveal more about how 
HIF functions as well as provide knowledge that can lead to development of novel 
compounds to treat cancer
76
.   
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2 Aims 
Based on the information provided in the previous sections, the following hypothesis and 
aims are outlined in the presented thesis: 
 
2.1 Hypothesis 
Hypoxia is associated with poor prognosis in many solid cancer types, and is connected to 
radiation resistance and resistance to chemotherapy. Cancer stem cells have also been 
connected to poor prognostics and reduced treatment efficacy. We therefore hypothesize that 
hypoxia induces stem-like traits in glioma cell lines. 
 
2.2 Aims 
I. Establish a protocol for culturing of cells in hypoxia. 
II.  Culture glioma cell lines in normoxia (21.0 % O2) and hypoxia (2.0 and 0.5 % O2), 
and investigate expression of cell line markers associated with different cell types in 
CNS. 
III. Investigate growth properties of glioma cell lines cultured in hypoxia compared to 
normoxia by looking at growth rates, cell division and apoptosis.  
IV.  Investigate migration properties of glioma cell lines in hypoxia and normoxia by the 
use of electric cell-substrate impedance sensing.  
Materials 
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3 Materials 
 
Table 3.1: Cell lines 
Name Source Catalogue nr. Distributor 
A172 Human glioblastoma CRL-1620 ATCC
1
, Manassas, 
Virginia, USA 
LN-18  Human glioblastoma CRL-2610 ATCC, Manassas, 
Virginia, USA 
NCH-644 Human Glioblastoma – Christine Herold-Mende, 
Dept. of Neurosurgery, 
University of Heidelberg, 
Heidelberg, Germany 
U-118 MG Human glioblastoma, astrocytoma HTB-15 ATCC, Manassas, 
Virginia, USA 
U-251 MG Human glioblastoma, astrocytoma Unavailable ATCC, Manassas, 
Virginia, USA 
U-87 MG Human glioblastoma, astrocytoma HTB-14 ATCC, Manassas, 
Virginia, USA 
 
Table 3.2: General chemicals and solutions 
Chemical/Solution Catalogue nr. Supplier 
Acetic acid, 100 % 1.00062.1000 Merck Chemicals, 
Darmstadt, Germany 
Acetone 1.00014.1000 Merck Chemicals, 
Darmstadt, Germany 
Agarose 3:1 50004 Lonza, Basel, Switzerland 
Annexin-V conjugated to FITC A13199 Molecular Probes 
(Invitrogen), Carlsbad, 
California, USA  
   
                                                   
1
 American Type Culture Collection 
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Benzamidine 12072 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Bovine serum albumin (BSA) A4503 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Difco Skim Milk Powder 232100 BD Biosciences, Franklin 
Lakes, New Jersey, USA 
Dimethyl Sulphoxide (DMSO) D2438 Sigma-Aldrich, St. Louis, 
Missouri, USA 
DNase 79254 Qiagen, Hilden, Germany 
Dulbecco’s Modified Eagle’s Medium (DMEM) D5671 Sigma-Aldrich, St. Louis, 
Missouri, USA 
EDTA ED2SS Sigma-Aldrich, St. Louis, 
Missouri, USA 
EGTA E4378 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Ethanol, absolute 32221 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Ethidium Bromide (EtBr), 10 mg/ml E1510 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Isopropalol 600079 Arcus Kjemi, Vestby, 
Norway 
L-Cysteine C7352-25G Sigma-Aldrich, St. Louis, 
Missouri, USA 
Leupeptin 108975 Merck Chemicals, 
Darmstadt, Germany 
L-Glutamine BE17605E Cambrex, New Jersey, 
USA 
Methanol (100%) 1060122500 Merck Chemicals, 
Darmstadt, Germany 
Molecular biology Grade H2O 955155025 Eppendorf AG, Hamburg, 
Germany 
MOPS (3-morpholinopropane-1-sulfonic acid) 475898 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Materials 
20 
Na-Orthovandate S6508 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Na-Pyrophosphate S6422 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Non-essential amino acids BE13114E Cambrex, New Jersey, 
USA 
NuPAGE 4-12 % Bis-Tris Gel NP0322BOX Invitrogen, Carlsbad, 
California, USA 
NuPAGE Antioxidant NP0005 Invitrogen, Carlsbad, 
California, USA 
Paclitaxel 86346 Fluka, Sigma-Aldrich, St. 
Louis, Missouri, USA 
Paraformaldehyde (PFA) powder 76240 Fluka, Sigma-Aldrich, St. 
Louis, Missouri, USA 
Penicillin/Streptomycin  DE17603E BioWhittacker Inc., 
Walkersville, Maryland, 
USA 
Pepsin, 0.5 %, pH 1.5  Sigma-Aldrich, St. Louis, 
Missouri, USA 
Pepstatin 516485 Merck Chemicals, 
Darmstadt, Germany 
Plasmocin ant-mpt InvivoGen, California, 
USA 
PMSF (phenylmethanesulfonyl fluoride) P7626 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Ponceau P3504 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Propidium iodide (PI) P4170 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Protein Assay Dye Reagent Concentrate  500-0006 BIO-RAD, Hercules, 
California, USA 
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RNA loading dye R0641 Fermentas, Thermo Fisher  
Scientific, Waltham, 
Massachusetts, USA 
SeeBlue Plus2 Prestained Standard (1x) LC5925 Invitrogen, Carlsbad, 
California, USA 
Sodium fluoride (NaF) 80373 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Soduim cloride (NaCl) S0390 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Tris Base 648310 Merck Chemicals, 
Darmstadt, Germany 
Triton X-100 T8787 Sigma-Aldrich, St. Louis, 
Missouri, USA 
Trypsin-EDTA 200 mg/L Versene BE17-161E Lonza, Basel, Switzerland 
Tween 20 170-6531 BIO-RAD, Hercules, 
California, USA 
Vectashield Mounting Solution w/DAPI H1200 Vector Laboratories, 
Burlingame, California, 
USA 
Virkon tablets for decontamination VIRKTABS Wilmington, Delaware, 
USA 
β-Glycerophosphate 35675 Merck Chemicals, 
Darmstadt, Germany 
 
Table 3.3: Commercial buffers 
Buffer Catalogue nr. Supplier 
Annexin binding buffer (5x): 50 mM HEPES, 
700 mM NaCl, 12.5 mM CaCl2, pH 7.4 
V13246 Molecular 
Probes/Invitrogen, 
Carlsbad, California, 
USA 
Dulbecco’s Phosphate Buffered Saline (10x) D1408 Sigma-Aldrich, St. Louis, 
Missouri, USA 
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NuPAGE LDS Sample Buffer (4x) NP0007 Invitrogen, Carlsbad, 
California, USA 
NuPAGE MOPS Running Buffer (20x) NP0001 Invitrogen, Carlsbad, 
California, USA 
NuPAGE Transfer Buffer (20x) NP0006-1 Invitrogen, Carlsbad, 
California, USA 
Phosphate buffered saline without calcium and 
magnesium (10x) 
04-409 Bio-Whittaker/Lonza, 
Basel, Switzerland 
 
Table 3.4: Buffers/solutions prepared in the lab 
Buffer Constituents 
Annexin binding buffer (1x)  Annexin binding buffer (5x) diluted 1:4 in 
MilliQ H2O 
Blocking buffer for ICC, 0.5%   250 μg bovine serum albumine dissolved 
in 50 ml MilliQ H2O, sterile filtered 
Blocking buffer for western blot, 5 % 2.5 g skim milk in TBST w. Tween 0.1 %, 
dissolved by vortexing 
Cell-freezing solution 0,5 ml DMSO, 0,5 ml 10% heat 
inactivated calf serum, 4 ml DMEM-ALT 
DMEM-ALT DMEM supplemented w. 10 % heat 
inactivated calf serum, four times the 
prescribed amount of non-essential amino 
acids, L-Glutamine, penicillin (100 μg/ml) 
and streptomycin (100 μg/ml) 
Dulbecco’s Phosphate Buffered Saline (1x) 1 volume of Dulbecco’s Phosphate 
Buffered Saline (10x), 9 volumes of 
autoclaved MilliQ H2O 
Fixation reagent, 4 % 4 g lyophilized PFA in 100 ml 1xPBS 
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Kinexus lysis buffer 500 mM MOPS, 500 mM EDTA, 100 mM 
EGTA, 500 mM NaF, 10 % Triton X-100, 
500 mM b-Glycerophosphate, 400 mM 
Na-Pyrophosphate (pH 7.0), 250 mM Na-
Orthovandate, 1 mM Pepstatin, 50 mM 
Leupeptin, 100 mM PMSF (in 
isopropanol), adjusted to pH 7.2 and 
expanded to 20 ml with ddH2O 
Permeabilizing reagent for fixed cells, 0.5 % 250 μl Triton X-100 dissolved in 50 ml 
MilliQ H2O 
Ponceau S 0.1 % Ponceau S, 5 % acetic acid 
Rinsing Buffer for WB (TBST) 20 ml 0.5 M Tris/HCl pH 7.5 + 75 ml 1M 
NaCl + 0.5 ml Tween 20. Adjusted to 500 
ml with MilliQ H2O 
Running buffer for SDS-PAGE 200 ml 1x NuPAGE MOPS running buffer 
(20xMOPS diluted with MilliQ H2O) and 
500 µl NuPAGE antioxidant 
Transfer buffer for WB 25 ml 20x NuPAGE transfer buffer, 50 ml 
100 % methanol, 500 µl NuPAGE 
antioxidant, adjust to 500 ml with MilliQ 
H2O 
Tris-HCl (1M) 121.14 g Tris Base dissolved in 900 ml 
MilliQ H2O, adjust pH to 7.5 
 
Table 3.5: Plastic and paper ware   
Article Catalogue nr. Supplier 
Chromatography paper, 3 mm 3030917 Whatman International 
Ltd., Kent, United 
Kingdom 
Cryo tubes 377267 Nunc, Thermo Fischer 
Scientific, Waltham, 
Massachusetts, USA 
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Nunc Easy flask with Nunclon Δ, 25 mm2 156367 Nunc, Thermo Fischer 
Scientific, Waltham, 
Massachusetts, USA 
Nunc Easy flask with Nunclon Δ, 75 mm2 156499 Nunc, Thermo Fischer 
Scientific, Waltham, 
Massachusetts, USA 
Parafilm “M” PM-966 Structure Probe, Inc., 
West Chester, 
Pennsylvania, USA  
Protran Nitrocellulose Transfer Membrane, 0.2 
µm 
10401396 Whatman International 
Ltd., Kent, United 
Kingdom 
Touch N Tuff Disposable Nitrile Gloves 92-600 Ansell, Red Bank, New 
Jersey, USA 
TPP Tissue Cell Scraper 99002 MidSci, St. Louis, 
Missouri, USA 
 
Table 3.6: Primary antibodies for ICC and Western Blot 
Anti-X 
antibody, 
application Dilution 
Source species 
and clonality Catalogue nr. Supplier 
BrdU (ICC) 1:100 Mouse 
monoclonal IgG 
Ab8152 Abcam, Cambridge, 
United Kingdom 
CD133 1:20 Mouse 
monoclonal IgG1 
AC141 Miltenyl Biotech GmbH, 
Bergisch Gladbach, 
Germany 
GAPDH (WB) 1:2500 Rabbit 
polyclonal IgG 
Ab9485 Abcam, Cambridge, 
United Kingdom 
GFAP (ICC) 1:500 Goat polyclonal 
IgG 
Sc-1672 Santa Cruz 
Biotechnology, Santa 
Cruz, California, USA 
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HIF-1α (ICC, 
WB) 
ICC 1:500 
WB 1:300 
Mouse 
monoclonal IgG1  
610959 BD Transduction 
Laboratories, Franklin 
Lakes, New Jersey, USA 
Nestin (ICC) 1:500 Rabbit 
polyclonal IgG 
Ab5922 Chemicon (Millipore), 
Billerica, Massachusetts, 
USA 
βIII -tubulin 
(ICC) 
1:100 Mouse 
monoclonal IgG 
MAB1637 Chemicon (Millipore), 
Billerica, Massachusetts, 
USA 
 
Table 3.7: Secondary antibodies 
Secondary 
Antibodies Dilution 
Type/source- 
species Catalogue nr. Supplier 
FITC 
conjugate 
1:200 Goat anti-mouse 
IgG1 
1070-02 Southern Biotech, 
Birmingham, Alabama, 
USA 
HRP 1:25 000 Goat anti-mouse 
IgG 
sc-2005 Santa Cruz 
Biotechnology, Santa 
Cruz, California, USA 
HRP 1:100 000 Goat anti-rabbit 
IgG 
sc-55226 Santa Cruz 
Biotechnology, Santa 
Cruz, California, USA 
Texas Red 
conjugate 
1:200 Goat anti-mouse 
IgG1 
1070-07 Southern Biotech, 
Birmingham, Alabama, 
USA 
Texas Red 
conjugate 
1:200 Goat anti-rabbit 
IgG 
4010-07 Southern Biotech, 
Birmingham, Alabama, 
USA 
Texas Red 
conjugate 
1:1000 Rabbit 
polyclonal anti-
goat IgG 
Ab 6738-1 Abcam, Cambridge, 
United Kingdom 
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Table 3.8: Primers
2
 for qRT-PCR 
Target gene Primer sequence 
TUBB3 Fw 5’ – TTT – AGA – CAC – TCC – TGG – CTT – CG – 3’ 
Rev 5’ – CGC – AGA – TGT – ACG – AAG – ACG – AC – 3’ 
CAIX Fw 5’ – CAC – CAG – CGT – CGC – GTT – CC – 3’ 
Rev 5’ – TAG – GCT – CCA – GTC – TCG – GCT – ACC – 3’ 
CD133 Fw 5’ – CAA – GAA – TTC – CGC – CTC – CTA – GCA – CT – 3’ 
Rev 5’ – ACC – AGG – TAA – GAA – CCC – GGA – TCA – A – 3’  
GAPDH Fw 5’ – GAG – TCA – ACG – GAT – TTG – GTC – GT – 3’ 
Rev 5’ – GAC – AGC – TTC – CCG – TTC – TCA – G – 3’ 
GFAP Fw 5’ – AGA – AGC – TCC – AGG – ATG – AAA – CC – 3’ 
Rev 5’ – AGC – GAC – TCA – ATC – TTC – CTC – TC – 3’ 
Nestin Fw 5’ – TCC – AGG – AAC – GGA – AAA – TCA – AG – 3 ’ 
Rev 5’ – GCC – TCC – TCA – TCC – CCT – ACT – TC – 3’ 
 
Table 3.9: Commercial Kits 
Article Catalogue number Producer 
iQ SYBR Green Supermix 170-8882 BIO-RAD, Hercules, 
California, USA 
iScript cDNA kit 170-8890 BIO-RAD, Hercules, 
California, USA 
Qiagen RNeasy Mini Kit 74106 Qiagen, Hilden, 
Germany 
Super Signal West Pico 
Chemiluminescent Substrate 
34080 Thermo Fischer 
Scientific, Waltham, 
Massachusetts, USA 
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 All primers are bought from Invitrogen, San Diego, California, USA. 
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Table 3.10: Hardware 
Name 
Catalogue 
number/Model Supplier 
Accuri Flow Cytometer C6 Accuri Cytometers 
Inc., Ann Arbor, 
Michigan, USA  
Asys UVM 340 Microplate Reader  G019065090 Biochrom Ltd., 
Cambridge, United 
Kingdom 
CO2 incubator  
 
MCO-19AIC (UV) SANYO Electric Co. 
Ltd., Moriguchi City, 
Osaka, Japan 
Confocal Microscope LSM 510 Meta Carl Zeiss 
Microimaging GmbH, 
Oberkocken, Germany  
Electric cell-substrate impedance 
sensing (ECIS) 
ECIS-Z Applied Biophysics 
Inc, Troy, New York, 
USA 
Fluorescence microscope Axioplan II Carl Zeiss 
Microimaging GmbH, 
Oberkocken, Germany 
Horizon58 Horizontal Gel 
Electrophoresis Apparatus 
41060 Biometra, Göttingen, 
Germany 
Hypoxia C-chamber  C-374 BioSpherix, Lacona, 
New York, USA 
Luminescent Image Analyzer LAS3000 Fujifilm Medical 
Systems Inc., Stamford, 
Connecticut, USA 
Novex Mini-Cell chamber – Invitrogen, Carlsbad, 
California, USA 
Peltier Thermal Cycler PTC-200 BIO-RAD, Hercules, 
California, USA 
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Roche’s Real time PCR system LightCycler 480 Roche, Basel, 
Switzerland 
Vibra Cell Sonicator VC130 Sonics & Materials 
Inc., Newton, 
Connecticut, USA 
 
Table 3.11: Software   
Program Version Supplier 
Adobe Photoshop CS5 Adobe Systems Inc., 
San Jose, California, 
USA 
DigiRead 1.0.2.0 Biochrom Ltd., 
Cambridge, United 
Kingdom 
ECIS software 1.2.2 Applied Biophysics 
Inc, Troy, New York, 
USA 
Flow-Jo 9.3.1 Tree Star Inc., Ashland, 
Oregon, USA 
Microsoft Office Excel 2003 Microsoft Corporation , 
Redmond, Washington, 
USA 
QuantPrime  
qPCR Primer designing tool 
2011 Free online program by 
Samuel Arvidsson, 
University of Potsdam, 
Potsdam, Germany 
Real Time PCR analysis software LCS480 Roche, Basel, 
Switzerland 
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4 Methods 
All procedures were performed at room temperature unless otherwise stated. 
4.1 Cells 
4.1.1 Cell culturing 
Glioma cell lines were kept at 37
o
C in tissue culture incubators at 100 % humidity with 5 % 
CO2
 
and 95 % air. The cells were grown as monolayers in 75 cm
2
 culture flasks (Nunc, 
Thermo Fischer Scientific, Waltham, Massachusetts, USA) to 80 % confluency before they 
were trypsinized and passaged as follows: Old medium was removed before the cells were 
washed twice with 1x phosphate buffered saline (1xPBS, Sigma Aldrich, St. Louis, Missouri, 
USA). The cells were detached by incubation at 37
o
C in Trypsin-EDTA (Lonza, Basel, 
Switzerland) for 3-5 minutes. Trypsin was inactivated by adding supplemented Dulbeccos 
Modified Eagles Medium (DMEM-ALT (table 3.4), Sigma Aldrich, St. Louis, Missouri, 
USA). Excessive cells were discarded and 15 ml fresh DMEM-ALT was added. Passage 
number was registered each time the cells were passaged. All work with cells was carried out 
wearing protective gloves and coat in a laminar flow bench (SANYO Electric Co, Osaka, 
Japan) that was sterilized with 70 % ethanol before and after use. Equipment used in the 
laminar flow bench was sterilized with 70 % ethanol or microwaved at full effect for two 
minutes. Cells were monitored using an inverted light microscope.  
 
4.1.2 Cryopreservation of cells 
Cells were frozen down for cryopreservation as soon as the first passaging of newly thawed 
cells. When approximately 80 % confluent, cells were trypsinized as previously described and 
transferred to a 15 ml centrifuge tube. The cell suspension was then centrifuged at 700 g for 
five minutes. After discarding the supernatant, pelleted cells were resuspended in 2 ml 
freezing solution (table 3.4), and then distributed into two cryotubes. Tubes were marked with 
cell line, passage number, date, and name of owner and placed in an isopropanol container for 
about 24 hours and frozen down to -80
o
C. Isopropanol ensures a slow decline in temperature 
of about 1
o
C per minute. The cryotubes were then placed in the N2-tank for cryopreservation 
at -196
o
C. Cryopreservation was done in order to keep a batch of cells from the same passage 
as reserve. If cells are kept in culture for a long time, typically more than 25 passages or two-
three months, the may change character due to genetic drift, selection or cross 
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contamination
77
. To achieve comparable results over time, it is therefore important to perform 
experiments within the same range of passages. 
 
4.1.3 Thawing of cells  
Cells were collected from the N2-tank and thawed by placing the cryotubes in a 37
o
C water 
bath. Immediately after thawing, the cell suspension was transferred to a culture flask 
containing 15 ml DMEM-ALT. After 24 hours incubation, the medium was changed to 
remove remnants of freezing solution which may otherwise harm the cells.  
 
4.1.4 Counting cells 
In some of the experiments, cells were counted prior to seeding or during the experiment. A 
Bürker chamber was used for determination of cell concentration. 10 μl of cell suspension 
was pipetted into the chamber. The chamber has a grid system of 3x3 large squares each with 
a volume of 10
-4
 ml. Cells in three large squares were counted and divided by three to achieve 
an average number of cells in one square. This number was multiplied by 10
4 
to give the 
number of cells in one ml.  
 
4.2 The hypoxia chamber 
The chamber used for the hypoxia experiments was the C-chamber from BioSpherix Ltd 
(Lacona, New York, USA). The dimensions of the chamber are 35x30x20 cm, which makes it 
fit into a warming cabinet to ensure physiological temperatures of 37
o
C. The chamber has two 
sensors, one that senses the CO2 concentration and one that senses the O2 concentration. Two 
regulators control the gas flow into the chamber through tubes connected to the back of the 
chamber. One regulator controls the flow of CO2 and one controls the flow of N2 into the 
chamber. Since it is a low oxygen chamber, N2 is pumped into the chamber to replace O2. The 
CO2 concentration was set to 5.0 % as in standard tissue culture incubators. The hypoxia 
experiments were performed at 2 % and 0.5 %, and the O2 concentration was set to the 
corresponding values. The sensors were calibrated using a mixture of 90 % N2 and 10 % CO2, 
100 % N2 and normal air (21 % O2). 
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4.2.1 Preparation of hypoxia conditioned cells for immunocytochemistry 
All experiments were done in 0.5 % O2 (from now on called hypoxia) and in the standard 
tissue culture incubator (from now on defined as normoxia). Only ICC was performed in 
hypoxia at 0.5 % and 2 % O2. Cells were seeded on coverslips at a density of 80,000 cells per 
well and fixed after 24 hours. Cells were also seeded at a density of 30,000 cells per well and 
fixed after four days. The plate was placed in the hypoxia incubator for the desired time. 
Fixation was done immediately after incubation (as explained in chapter 4.3.2) and stored in 
PBS at 4
o
C until use. 
 
Cells were also grown in culture flasks in the hypoxia chamber. These flasks were used to 
prepare cells that were conditioned with hypoxia for a longer period of time. For the ICC 
experiments cells were fixed after eight days, twelve days, and after four weeks in hypoxia. 
Two days before each fixation cells were collected from the cell flask and seeded onto 
coverslips in 24-well plates. The well plates were subsequently put back into the hypoxia 
chamber and incubated for two more days until fixation.  
 
4.2.2 Other experiments with hypoxia conditioned cells 
Cells were grown in culture flasks until the time point when RNA isolation, protein extraction 
or preparation for flow cytometry was performed. The ECIS equipment (chapter 4.6.5) was 
also installed inside the hypoxia chamber. For the experiments in hypoxia, one or more of five 
different glioma cell lines U-251, A172, U-118, LN-18 and U-87 (table 3.1) were used. For 
each experiment, control cells were always incubated in normoxia for the same period of time 
and were exposed to the same treatment. 
 
4.3 Immunocytochemistry 
4.3.1 Immunocytochemistry 
Immunocytochemistry (ICC) is a technique for detecting a protein of interest inside or on the 
membrane of cells. The protein is identified by using an antibody conjugated to a fluorescent 
tag – a fluorophore. Immunostaining can then be investigated using different techniques, for 
example fluorescence microscopy and confocal microscopy. One can distinguish between 
direct and indirect ICC. In direct ICC, only a primary fluorophore-conjugated antibody is 
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used. In indirect ICC, a primary antibody is allowed to bind to the target protein first, and then 
a secondary fluorophore-conjugated antibody binds to the primary antibody. Indirect ICC is 
more sensitive because several secondary antibodies can bind to a single primary antibody, 
thus enhancing the signal. 
 
4.3.2 Preparation of cells 
For immunostaining, cells were seeded on sterile 10 mm coverslips in a 24-well plate. 
Approximately 50,000 cells were seeded in each well, and then incubated with DMEM-ALT 
for the desired time. Cells were then washed twice with 1xPBS and fixed using 4 % 
paraformaldehyde (PFA, fixation reagent, table 3.4) as follows: Each coverslip was covered 
in PFA for 10 minutes. PFA was removed and the cells were permeabilized with 0.5 % Triton 
X-100 (Zigma-Aldrich) for four minutes. Triton X-100 was then removed and cells were 
washed three times with 1xPBS and stored in 1xPBS at 4
o
C until use. 
 
Non-adherent cells that were used to perform ICC were cytospun to object glass slides for 3 
minutes at 800 g. Cells were then fixed in ice cold acetone for 10 minutes and stored in -20
o 
C 
until use. 
 
4.3.3 Immunostaining 
The procedure for immunostaining was done at the lab bench. Staining was done by pipetting 
30 μl droplets of the various solutions onto a parafilm-covered bottom of a flat plastic box. 
The coverslips were moved from droplet to droplet using tweezers. The cells were first 
incubated in blocking buffer for ICC (table 3.4) for 15 minutes to prevent unspecific binding 
of the antibody. Then the cells were incubated with primary antibody diluted in blocking 
buffer for 45 minutes at 37
o
C. A wet paper towel in the box prevented the coverslips from 
drying out. After incubation, cells were washed with 1xPBS 2x3 minutes. Incubation with 
secondary antibody diluted in blocking buffer was done for 45 minutes at 37
o
C. The 
coverslips were then washed 3x3 minutes before dipped in MilliQ water to remove salts. 
Finally the coverslips were mounted onto object glasses with 5 μl Vectashield mounting 
solution containing DAPI (Vector Laboratories, Burlingame, California, USA). DAPI stains 
the nucleus of the cell by binding to DNA. The mounting solution was allowed to dry for at 
least one hour before it was secured with nail polish. Every step from incubation with 
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secondary antibody and onwards was done without bench light. All immunostainings were 
done with negative controls by omitting the primary antibody. 
 
4.3.4 Confocal imaging 
In a regular fluorescence microscope, the whole specimen is excited at the same time, and this 
gives a certain background and blur in the image. The principle of confocal imaging is the use 
of a pin hole to avoid detection of emitted light that is outside the focal plane. The pin hole is 
situated on the other side of two lenses where the focal point creates an image. The pin hole 
and focal point are positioned confocal to each other, hence the name of the microscope. This 
allows only the emitted light from the focal point, which has the highest intensity, to be 
detected while all other light is excluded. When light is emitted by the specimen and focused 
through the pin hole it is detected by the photomultiplier tube connected to a computer. Only 
one spot (pixel) in the specimen is detected at a time, and the computer builds up an image as 
a chosen number of pixels detected. The confocal microscope used to examine and image the 
ICC experiments performed in this project was the Zeiss LSM 510 Meta (Carl Zeiss, 
Oberkochen, Germany) located in the Molecular Imaging Center (MIC), Bergen. Zeiss LSM 
510 Meta is equipped with several lasers, of which the UV laser was used to excite at 358 nm 
(DAPI), the Argon laser was used to excite at 488 nm (FITC) and the HeNe laser was used to 
excite at 543 nm (Texas Red).  
 
4.4 SDS-PAGE and Western Blotting 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) is used to separate 
proteins according to size. This is achieved through the use of SDS, which denatures the 
proteins so they all have a linear shape in addition to giving them a negative charge. Like that 
they all migrate towards the positive pole in the PAGE, and they are separated on the gel by 
their size. The separated proteins can be transferred to a membrane and thereafter be detected 
by the use of epitope specific antibodies that bind to the proteins on the membrane.  
4.4.1 Protein isolation 
Cell flasks were kept on ice while they were washed twice with 3 ml ice cold 1xPBS. 150 µl 
Kinexus protein lysis buffer (with Triton X-100 to disrupt cell membranes, protease inhibitors 
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to protect from protein degradation and phosphatase inhibitors that protect from protein 
dephosphorylation) was added, and a cell scraper was used to loosen the cells. The cell-lysis 
buffer suspension was transferred to a 1.5 ml eppendorf tube and incubated for 10 minutes on 
ice. A sonicator (Sonics Vibra Cell, Newton, Connecticut, USA) was used at 20 Hz for 3x2 
seconds to further disrupt the cell membrane and homogenize the intracellular content. The 
samples were then centrifuged for 30 minutes at 4
o
C and maximum speed (16,000 g) in an 
eppendorf microcentrifuge. The supernatant which contains the protein was transferred to a 
new 1.5 ml eppendorf tube and stored at -80
o
C until use. 
 
4.4.2 Determination of protein concentration 
1.5 µl of each sample was mixed with 788.5 µl MilliQ H2O, 10 µl lysis buffer and 200 µl dye 
reagent concentrate for protein assay (BIO-RAD, Hercules, California, USA) to a final 
volume of 1000 µl per sample. For each sample 200 µl of this solution was transferred to a 96 
well plate for spectrophotometric analysis at 595 nm (ASYS UVM 340 with DigiRead 
Microplate Instrumentation Control). A standard curve for determination of protein 
concentration was made by measuring absorbance at 595 nm for a series of six dilutions of 
BSA (0, 1, 2, 4, 6 and 10 μg). Microsoft Office Excel (Microsoft Corporation, Redmond, 
California, USA) was used for the calculations and interpolations on the standard curve. 
 
4.4.3 SDS-PAGE 
Samples were prepared to a final volume of 18 µl as shown in table 4.4.3. The samples were 
boiled at 70
o
C for 10 minutes. The Novex mini-cell gel chamber (Invitrogen, Carlsbad, 
California, USA) was used together with a 12-well NuPage 4-12 % Bis-Tris gel (Invitrogen). 
The inner chamber was assembled first and filled with 200 ml 1x NuPage MOPS SDS 
Running Buffer with 500 µl antioxidant (Invitrogen). The wells of the gel were flushed with 
running buffer before loading to remove air. 7 µl SeeBlue Plus2 Prestained Standard 
(Invitrogen) and 15 µl of each sample mixture were loaded and the outer chamber filled with 
1x running buffer. The gel was run for 50 minutes at 200 V.  
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Table 4.4.3: Loading mixture for SDS-PAGE 
Sample 
10 μg 
protein 
(in µl) 
10X DTT 
(µl) 
4X LDS buffer 
(µl) 
MilliQ H2O 
(µl) 
Total volume 
(µl) 
1 x 1.8 4.5 x 18 
 
4.4.4 Blotting 
Transfer buffer was prepared as described in table 3.4. The nitrocellulose membrane, sponges 
and filter paper were soaked in transfer buffer before assembling with the gel. The transfer 
chamber was filled with transfer buffer and the outer chamber with MilliQ H2O. Blotting was 
run for 80 minutes at 30 V. 
 
4.4.5 Ponceau S staining 
After blotting, the nitrocellulose membrane was washed in MilliQ H2O. The membrane was 
incubated for seven minutes with ponceau stain to verify that the protein had been transferred 
to the membrane. Ponceau S is a red dye that binds to proteins. The binding is reversible, and 
after staining it is easily washed off with MilliQ H2O. 
 
4.4.6 Blocking and antibody incubation 
Blocking buffer for western blot was prepared from 2.5 g skim milk powder in 50 ml rinsing 
buffer (materials table 3.4). The blot was then blocked with gentle agitation for 1 hour in 
room temperature. Primary and secondary antibodies were diluted to the desired dilution in 
blocking buffer. The membrane was incubated with primary antibody solution with agitation 
over night (4
o
C). The blot was then washed with rinsing buffer on a shaking board for 4x10 
minutes before incubation with secondary antibody solution for 1.5 hours with gentle 
agitation (room temperature). The blot was washed in rinsing buffer again for 4x10 minutes 
on a shaking board.  
 
4.4.7 Chemiluminescence 
Blots were developed with the Super Signal West Pico Chemiluminescent Substrate (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). The kit contains an enhanced 
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chemiluminescent substrate for antibody conjugated horseradish peroxidase (HRP). The blots 
were allowed to absorb the substrate for five minutes before excess liquid was removed. The 
development was done with a luminescent image analyzer (Fujifilm Medical Systems Inc., 
Stamford, Connecticut, USA). 
 
4.5 qRT-PCR 
qRT-PCR (quantitative reverse transcriptase polymerase chain reaction) is based on the 
standard PCR-reaction. The additional feature of qRT-PCR is the use of an intercalating 
fluorescing dye from which the signal increases throughout the reaction. This is used to 
follow the amplification and to quantify the starting amount of DNA. 
 
4.5.1 RNA isolation 
Cells were washed twice with 1xPBS before incubation at 37
o
C with 0.5 ml trypsin for 3-5 
minutes. Trypsin was inactivated by adding 3 ml DMEM-ALT and the cells transferred to a 
15 ml centrifugation tube and spun down at 700 g for 5 min. The supernatant was removed 
and the cells were washed in 1xPBS and spun down again at 700 g for 5 minutes. RNeasy 
Mini Kit (Qiagen, Hilden, Germany) was used for RNA extraction according to the 
manufacturer’s manual.  
 
RNA was isolated three times from glioma cell lines both maintained in normoxia, and 
incubated in hypoxia at 0.5 % O2 for eight days.  
 
4.5.2 Determination of RNA concentration and quality 
RNA concentration was determined with the NanoDrop1000 Spectrophotometer (Thermo 
Fisher Scientific). The RNA quality was reassured with agarose gel electrophoresis. 2 µl of 
RNA was run with 2 µl 2x RNA loading dye (Fermentas, Thermo Fisher Scientific) on a 1 % 
agarose gel with ethidium bromide (Zigma-Aldrich) at 90 V for 35 minutes. The bands were 
visualized using an UV-imager (Fujifilm Medical Systems Inc., Stamford, Connecticut, 
USA). If the RNA is intact and no genomic DNA is present in the samples, two distinct bands 
corresponding to the 18S and 28S ribosomal subunits are visual (figure 5.1.3.1).  
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4.5.3 cDNA synthesis 
cDNA was synthesized from 250 ng RNA with the iScript cDNA synthesis kit (BIO-RAD, 
Hercules, California, USA). To minimize the use of reagents, the volumes indicated in the 
protocol were halved. The Peltier Thermal Cycler (BIO-RAD) was used for the cDNA 
synthesis with the reaction set up and PCR program as shown in table 4.5.3 below.   
 
Table 4.5.3: Raction set up (a) and PCR program (b) for cDNA synthesis 
a) Reagents µl  b) cDNA program 
o
C 
5X cDNA synthesis kit buffer 
iScript enzyme mixture 
RNA sample 
Nuclease-free water  
5 
0,5 
x 
x 
 5 min  
30 min  
5 min  
Hold 
25 
42 
85 
4 
Total volume  10    
 
After cDNA synthesis the cDNA was diluted 1:10 by adding 90 µl molecular grade water and 
stored at -80
o
C until use. 
 
4.5.4 qRT-PCR 
For qRT-PCR the iQ SYBR Green Supermix kit (BIO-RAD) was used with the setup shown 
in table 4.5.4. A master mix was made from the SYBR Green Supermix, primer pairs and 
H2O before distributing it into the wells, and then cDNA was added.  
 
Table 4.5.4: Reaction setup (a) and program for qRT-PCR (b) 
a) Reagent µl  b) qRT-PCR program 
o
C Time 
iQ SYBR Green Supermix 10  Initial denaturation 95 5 min 
Primer pairs (1 µM) 4  Denaturation 95 10 sec 
cDNA (template) 1  Annealing 60 10 sec 
Molecular grade H2O 5  Extension 72 10 sec 
Total volume 20  Final extension 72 5 min 
  Hold 4 for ever 
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qRT-PCR was performed in 96/384 well plates on Roches LightCycler 480 Plate-based Real-
time PCR System (Roche, Basel Switzerland). Each gene was investigated in three isolated 
RNA samples, and each sample was run in triplets.  
   
The qRT-PCR results were analyzed with the LCS480 software (Roche) and exported to 
Excel for ΔΔCT-analysis. Student’s t-test was used to test for statistical significance.  
 
4.6 Quantification of proliferation, migration and cell death 
4.6.1 Growth curves 
To examine how the cells would grow in hypoxia compared to normoxia, growth curves for 
three cell lines (LN-18, U-251 and U-87) were established. For each cell line 10,000 cells 
were seeded in each of six small cell flasks. Three of the flasks were incubated in the hypoxia 
chamber and three in the standard tissue incubator. Cells in one flask were counted on the 
days three, six and nine, respectively. The number of cells in each flask was determined with 
the Bürker chamber and the numbers plotted in Excel to display them as a growth curve. The 
experiment was repeated three times.  
 
4.6.2 BrdU-pulsing and S-phase quantification 
Bromodeoxyuridine (BrdU) is a thymidine analogue complementary to adenosine. When 
supplied to the cell medium (pulsing) it is taken up by the cells. BrdU is then utilized by the 
cells during DNA synthesis in the S-phase of the cell cycle and is replacing thymidine. 
Immunocytochemistry can be used to visualize the cells that have incorporated BrdU. In our 
experiment cells were incubated in hypoxia for nine days, the two last on coverslips. The cells 
were then pulsed with BrdU (Abcam, Cambridge, UK) and incubated for 45 minutes in 37
o
C. 
Cells in normoxia were used as a control. The cells were fixed in 4 % PFA according to the 
protocol for ICC (chapter 4.3.2). Before incubation with the primary anti-BrdU antibody, 3 μl 
DNase (1 U/μl, Qiagen) was added to the antibody solution. This was done to denature the 
DNA strands to enable the antibody to bind to the incorporated BrdU. A FITC-conjugated 
secondary antibody (table 3.7) was then added in order to investigate the cells using 
fluorescence microscopy. DAPI was used as nuclear stain. Cells on ten different spots on the 
coverslip were counted, and the percentage of BrdU-positive cells quantified.  
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4.6.3 Flow cytometric analysis of the cell cycle distribution 
Cell cycle analysis by flow cytometry (FCM) can be used to assess the fraction of dividing 
cells in a collected cell sample. The analysis can also be used to detect aneuploidity, typically 
seen in cancer cells. Forward scatter is used to detect the size of each event passing the laser 
beam. Since the size will be proportional to the amount of DNA, two main populations will 
come up, one with nuclei from cells that are in the G1-phase and one with nuclei from cells 
that are in the G2-phase. Events with other amounts of DNA than these two will distribute 
around these two peaks. Below the G1-peak one finds the sub-G1 nuclei from debris and dead 
cells. The S-phase nuclei will be between the G1 and G2 peak. Aneuploid cells will give a shift 
in the peaks along the x-axis compared to the normal cells. 
 
Before cell cycle analysis 200,000 cells from the LN-18 cell line were seeded in each well in 
a six well plate and incubated in hypoxia for three days. Cells were trypsinized and collected 
by centrifugation at 700 g for 5 minutes. The supernatant was discarded and the pellet washed 
in 5 ml 1xPBS and centrifuged again at 700 g for 5 minutes. The supernatant was removed 
and the cells were fixed by adding 6 ml ice cold (-20
o
C) absolute ethanol drop by drop while 
vortexing. Fixed cells were spun down at 900 g for 5 minutes and the supernatant was 
removed. Cells were resuspended in 3 ml 0.5 % pepsin (Sigma-Aldrich) in PBS without 
calcium (pH 1.5, Bio-Whittacker/Lonza) and incubated for 15 minutes in a water bath (37
o
C). 
The suspension was spun down at 900 g for 5 minutes and the supernatant carefully removed. 
The pellet was washed in 5 ml 1xPBS without calcium and magnesium and spun down at 900 
g for 5 minutes. The supernatant was carefully removed and 100 μl RNase (1 mg/ml) in PBS 
and 300 μl propidium iodide (PI, 50 μg/ml, Sigma-Aldrich) were added. The solution was 
vortexed and incubated for 30 minutes at room temperature. The same procedure was used to 
prepare control cells in normoxia and the experiment was done twice.  
 
4.6.4 Annexin-V assay for flow cytometric quantification of cell death  
Phosphatidylserine (PS) is a negatively charged phospholipid found in the inner leaflet of the 
plasma membrane of live cells. When a cell enters apoptosis, translocase enzymes that are 
responsible for maintaining asymmetry in the lipid bilayer are inactivated. At the same time 
scramblases that exchanges random lipids between the lipid bilayers are activated. The result 
is externalization of PS in apoptotic cells. Annexin-V is a human anticoagulant with a high 
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affinity for PS. FITC conjugated Annexin-V can therefore be utilized to detect apoptosis in 
vitro as done here by flow cytometry. Because propidium iodide does not permeate the cell 
membrane, PI was used to distinguish early apoptotic cells from late apoptotic and necrotic 
cells, whose nuclei will become stained by PI.  
 
For the Annexin-V assay, 200,000 cells from the cell line LN-18 were seeded in each well in 
a six well plate and incubated in hypoxia for three days. Cells were trypsinized and collected 
by centrifugation at 1000 g for five minutes. In order to include dead cells floating in the 
medium at the moment of harvest, the old medium was saved and added again to inactivate 
the trypsin. The sample would then comprise both dead and alive cells from before 
harvesting. Cells were washed in 1xPBS and centrifuged at 1000 g for 5 minutes. The pellet 
was resuspended in 100 μl Annexin-V binding buffer (table 3.4). Two samples were used to 
prepare for color compensation in the flow cytometric analysis, one was stained only with PI 
(100 μl, 1 μg/ml) and one was stained only with FITC conjugated Annexin-V (5 μl, Molecular 
Probes, Invitrogen). One sample was also kept unstained. Samples for the apoptosis assay 
were stained both with PI and with FITC conjugated Annexin-V. Samples treated with the 
cytostatic drug Paclitaxel (Fluka, Sigma-Aldrich) were used as a positive control to ensure 
that the apoptosis assay had worked. Before analysis the samples were incubated in room 
temperature for 15 minutes. The same procedure was used to prepare control cells in 
normoxia and the experiment was done twice. The samples were analyzed on the Accuri C6 
flow cytometer (Accuri Cytometers Ltd., Ann Arbor, Michigan, USA). 
 
4.6.5 Wound healing assay with ECIS 
Electric cell-substrate impedance sensing – ECIS (Applied BioPhysics Inc., Troy, New York, 
USA) is based on specialized eight well arrays with gold-covered 250 μm electrodes with a 
small alternating current. The cell membrane acts as an insulator to the current, and as the 
cells seeded into the wells increase in numbers, the resistance to the current increases 
proportionally. The array is connected to electronics and computer software that is used to 
detect the changes in resistance and display the collected data as a line graph.  
 
Here, the ECIS was used to perform a wound healing assay to compare migration properties 
of cells in normoxia and hypoxia. The cell lines U-251 and LN-18 were chosen for the 
experiment. Before use, the electrode-array was incubated with 200 μl of 10 mM L-cysteine 
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(Sigma-Aldrich) solution for 10 minutes in 37
o
C. This was to cover any oxidized parts of the 
electrode, that otherwise could influence the cells. The L-cysteine solution was removed 
before seeding 400 μl cell suspension containing 100,000 cells into each well. The array was 
incubated for one hour to allow the cells to attach before connecting it to the electronics. The 
current used for continuous measurements of impedance was set to 32 kHz and data was 
collected every five minutes. When the cell layer approached confluency, the wounding was 
performed by applying 48 kHz to the cells at amplitude 2.5 V for 20 seconds. A dramatic drop 
in impedance would confirm that wounding had taken place, and the time was measured until 
the impedance had reached the same level as before wounding. The experiment was 
performed in hypoxia and normoxia sequentially.  
 
 
Figure 4.6.5: Schematic overview of the ECIS equipment. Cell density 
measurements and wounding is taking place on the 250 μm electrode 
indicated in blue. 
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5 Results 
In the present study, five glioma cell lines (A172, LN18, U87, U118, U251) were investigated 
with respect to their expression of the cell line markers CD133, Nestin, β-III tubulin and 
GFAP under hypoxic and normoxic conditions. Some cell lines in the panel were chosen in 
order to further explore aspects of glioma cell behavior, including proliferation, apoptosis and 
migration in hypoxia at 0.5 % oxygen compared to normoxia. 
5.1 A hypoxic environment was confirmed by stabilization of the 
transcription factor HIF-1α and upregulation of its downstream 
target CAIX 
5.1.1 ICC confirms nuclear HIF-1α expression 
Initially, immunocytochemistry (ICC) was performed on a panel of five glioma cell lines to 
investigate whether stabilization of HIF-1α takes place in the hypoxic environment created in 
the hypoxia chamber used (chapter 4.2, n = 2). 
 
Figure 5.1.1.1: Upper panels show confocal images of different glioma cell lines immunostained for HIF-1α 
as indicated in 21 % oxygen. Lower panels show corresponding immunostainings for HIF-1α after 
incubation in 0.5 % oxygen for 24 hours. Scale bars = 20 μm, nuclear counterstaining: DAPI (blue), HIF-
1α: Texas Red (red).  
 
Under normoxic conditions, we observed no staining for HIF-1α, neither in the nuclei nor in 
the cytoplasms. (Figure 5.1.1.1, upper panels). However, when cultured for 24 hours in 
hypoxia at 0.5 % oxygen nuclei in the same cell lines stained uniformly red (Figure 5.1.1, 
lower panels), indicating the presence of HIF-1α. Confocal imaging, which only displays 
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signals from one focal plane at a time, confirmed that HIF-1α was translocated to the nucleus 
and not other cellular compartments which were superimposed on the nuclei.  
 
Also, ICC for HIF-1α was performed on cells incubated in hypoxia for 24 hours at 2 % 
oxygen (Figure 5.1.1.2, upper panels, representative images). In 2 % oxygen nuclei also 
stained red, although the intensity of nuclear staining was slightly weaker than after 
incubation in hypoxia at 0.5 % oxygen. 
 
 
Figure 5.1.1.2: Confocal images of glioma cell lines immunostained for HIF-1α on 
cells incubated in hypoxia at 2 % oxygen for 24 hours (upper panel), and on cells 
incubated in hypoxia at 0.5 % oxygen for five weeks (lower panel). Representative 
images are shown for two of the cell lines, n = 2. Scale bars = 20 μm, DNA = DAPI 
(blue), HIF-1α = Texas Red (red). 
 
Additionally, ICC was performed on the same panel of cell lines after culturing them in 
hypoxia at 0.5 % oxygen for five weeks (figure 5.1.1.2, lower panels, representative images). 
After five weeks, HIF-1α was not detectable in the nucleus anymore, in contrast to what was 
seen after 24 hours in hypoxia. 
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5.1.2 Western blotting of HIF-1α 
In order to further confirm the stabilization of HIF-1α in hypoxia, we also performed western 
blotting. In accordance with the ICC, the protein for western blotting was isolated after 
incubating cells in small culture flasks for 24 hours in hypoxia at 0.5 %. Proteins from 
normoxic cells was isolated after maintaining cells in a standard incubator with 21 % oxygen 
as control (n = 1). 
 
Figure 5.1.2: Western blotting of protein lysates from the panel of cell lines maintained in normoxia and 
after incubation in hypoxia for 24 hours. The five left lanes are the samples from normoxia, and the five 
right lanes represent the same cell lines cultured in hypoxia at 0.5 % oxygen. GAPDH (40 kDa) was used 
as an internal loading control. 
 
The HIF-1α subunit is detected at 120 kDa, and when cultured in normoxia only (figure 5.1.2, 
left), cell lysate gave no visible band corresponding to the HIF-1α protein subunit. On the 
other hand, 24 hours incubation in hypoxia at 0.5 % oxygen (figure 5.1.2, right) produced 
bands at 120 kDa in all cell lines. However, the amount of HIF-1α protein varied between the 
different cell lines after incubation in hypoxia. 
 
5.1.3 Expression of CAIX investigated by qRT-PCR 
Carbonic anhydrase IX is a transcriptional target of HIF-1α, and is therefore expected to 
become upregulated in hypoxia. Here, CAIX expression was investigated by qRT-PCR to 
validate a transcriptional response in the cells under hypoxic conditions, and to corroborate 
the findings done by ICC and western blotting of HIF-1α (chapter 5.1.1 and 5.1.2, n = 3). 
Figure 5.1.3.1 shows a representative picture of RNA samples run on an agarose gel for RNA 
quality control (chapter 4.5.2). The isolated RNA was used for investigation of CAIX and cell 
line marker expression. 
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Figure 5.1.3.1: A representative picture of RNA on an agarose gel as aquality control. The 
bands representing the two ribosomal subunits (28S and 18S) indicate good RNA quality 
when they are distinct and the 28S band has approximately the double intensity of 18S.  
 
 
Figure 5.1.3.2: qRT-PCR results for CAIX displayed as fold change of mRNA levels in cells cultured in 
hypoxia at 0.5 % oxygen for eight days compared to mRNA levels of normoxic cells which are set to one. 
Standard error of the mean is indicated for each sample. 
 
All five cell lines showed an upregulation, although not significant, of CAIX in hypoxia. The 
magnitude of upregulation varied considerably between the different cell lines. It is evident 
from figure 5.1.3.2 that A172 (p = 0.289) had the highest upregulation of CAIX in hypoxia 
after eight days incubation, while U118 (p = 0.153) and U251 (p = 0.347) also expressed 
higher amounts of CAIX when cultured in hypoxia for eight days. U87 (p = 0.324) and LN18 
(p = 0.061) show a slight upregulation of CAIX in hypoxia.  
 
5.2 Expression of cell line markers 
GBMs are heterogeneous tumors with cells expressing markers of different CNS cell lineages. 
It is known that portions of GBM cells express markers associated with stem cells
56
. In order 
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to investigate whether hypoxia could induce stem cell features in cultured glioma cell lines, 
expression of four different cell line markers was investigated using ICC and qRT-PCR. The 
markers CD133, Nestin, GFAP and βIII-tubulin were chosen because they represent different 
stages of maturity and lines of differentiation. CD133 and Nestin are markers of neuronal 
stem cells whereas GFAP and βIII-tubulin are expressed by mature astrocytes and neurons, 
respectively. 1.5 % oxygen is defined as tumor hypoxia
79, 80
. Furthermore 1.5 – 2 % oxygen is 
reported to activate HIF-1α at its half maximal activity, whereas HIF-1α reaches its maximal 
activity at 0.5 % oxygen
81
. Therefore, oxygen concentrations for the hypoxia experiments 
were set to 2 % and 0.5 %.  
 
5.2.1. Expression of cell line markers in hypoxia – qRT-PCR  
To quantitatively assess the expression of cell line markers, the expressions of CD133 (results 
not shown), Nestin, βIII-tubulin and GFAP were examined in hypoxia and normoxia by qRT-
PCR. As for assessment of CAIX expression, RNA was isolated from glioma cell lines 
cultured in hypoxia at 0.5 % for eight days in order to perform qRT-PCR, and fold change 
was calculated by comparison to expression in normoxia (n = 3).  
 
 
Figure 5.2.1: qRT-PCR results for Nestin, GFAP and βIII-tubulin (TUBB3). Results are displayed as 
relative expression by fold change of mRNA levels of cells cultured in 0.5 % oxygen for eight days 
compared to cells maintained in normoxia, with normoxic gene expression set to one. Standard error of 
the mean is indicated together with an asterisk for those results that display statistical significance (p ≤ 
0.05). U251 is the only cell line expressing GFAP. 
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All markers investigated were downregulated after eight days in hypoxia at 0.5 % when 
compared to gene expression in normoxia (figure 5.2.1). Still, not all markers were 
significantly downregulated in hypoxia. U251 is the only cell line expressing GFAP, and 
according to qRT-PCR results for hypoxia, GFAP was downregulated to ca. one fifth of 
normoxic expression levels (p = 0.055). All cell lines were negative for CD133 also after 
eight days incubation in hypoxia. Interestingly, Nestin and βIII-tubulin showed similar 
magnitude of downregulation in all cell lines. However, Nestin was slightly more 
downregulated than βIII-tubulin in all cell lines except U87. Furthermore, downregulation of 
Nestin and βIII-tubulin is much stronger in LN18, U251 and A172 than in U118 and U87. 
Students t-test shows significant differences in expression of Nestin in LN18 (p = 0.005), 
U251 (p = 0.021), A172 (p = 0.008) and U118 (p = 0.006), whereas downregulation of βIII-
tubulin is significant in LN18 (p = 0.007) and A172 (p = 0.008). Downregulation of βIII-
tubulin was not statistically significant in U251 (p = 0.064), U118 (p = 0.135) or U87 (p = 
0.656), and neither was downregulation of Nestin in U87 (p = 0.971).  
 
5.2.2 Expression of cell line markers in hypoxia – immunocytochemistry 
The half life of intermediate filaments like Nestin and GFAP is reported to be eight days
82
, 
and microtubules are highly dynamic
83
. The time span of 4-12 days was therefore chosen, 
because it should be adequate to detect differences in protein expression. Cells were also 
cultured in hypoxia at 0.5 % oxygen for five weeks to see the long time effect of hypoxia on 
the expression of cell line markers. Expression of CD133, Nestin, βIII-tubulin and GFAP on 
cells incubated in hypoxia at 2 % and 0.5 % oxygen and in normoxia was investigated under a 
fluorescent microscope. ICC data is shown for cells cultured in normoxia and for cells 
cultured in hypoxia at 0.5 % oxygen for eight days. 
 
To examine the induction stemness in glioma cell lines cultured in hypoxia, expression of 
CD133 in the previously described panel of five glioma cell lines was investigated in hypoxia 
at 0.5 % oxygen and in normoxia (figure 5.2.2.1). We also included the NCH-644 (table 3.1), 
which is a primary glioma cell line enriched for CD133 positive cells as the positive control. 
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Figure 5.2.2.1: Upper panels show confocal images of glioma cell lines immunostained for CD133 in cells 
kept in standard conditions with 21 % oxygen for a few passages. Lower panels show CD133 expression in 
cell lines from the same cultures after incubation in 0.5 % oxygen for eight days. Scale bars = 20 μm, 
nuclear counterstaining: DAPI (blue), CD133: FITC (green). CD133 expression has been compared to the 
positive control NCH-644 (right). NCH-644 is a non-adherent primary cell, all samples have therefore been 
cytospun and fixed according to chapter 4.3.2 before staining. 
 
ICC revealed no CD133 expression neither in normoxia nor in hypoxia, which suggests that 
hypoxia that hypoxia does not induce stem cell like features in the five glioma cell lines 
investigated here (n = 2).  
 
Figure 5.2.2.2: Upper panels show confocal images of glioma cells immunostained for Nestin after cultured 
in 21 % oxygen for a few passages. Lower panels show staining for Nestin in cell lines from the same 
cultures after incubation in 0.5 % oxygen for eight days. Scale bars = 20 μm, nuclear counterstaining: 
DAPI (blue), Nestin: Texas Red (red). 
 
Expression of Nestin was examined by ICC after maintaining the panel of cell lines in 
normoxia and after incubation of the same cell lines for eight days in hypoxia at 0.5 % oxygen 
(figure 5.2.2.2). All cells in the three cell lines A172, U251 and LN18 are stained positive for 
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Nestin, regardless of oxygen concentration. Both the U87 and U118 contained a mixture of 
Nestin positive and negative cells, but the staining pattern did not differ between cells 
cultured in normoxia vs. hypoxia. LN18 seemed to have a more nuclear distribution of the 
protein, while the other cell lines solely showed cytoplasmic staining (n=2).  
 
Figure 5.2.2.3: Upper panels show confocal images of immunostaining for βIII-tubulin in cells cultured in 
21 % oxygen for a few passages. Lower panels show immunostaining of βIII-tubulin in cell lines from the 
same cultures after incubation in 0.5 % oxygen for eight days. Scale bars = 20 μm, nuclear 
counterstaining: DAPI (blue), βIII-tubulin: Texas Red (red). 
 
βIII-tubulin is the isoform of the microtubule β-subunit mainly found in neurons, and is 
therefore commonly used as a neuronal marker. Expression of βIII-tubulin was examined by 
ICC after maintaining the panel of cell lines in normoxia and after incubation for eight days in 
hypoxia at 0.5 % oxygen (figure 5.2.2.3). Expression of βIII-tubulin was seen in all cell lines 
with no clear difference between the two conditions. All cell lines showed both positively and 
negatively stained cells, with positive cells showing a filamentous distribution of the protein. 
In some cells filaments spread throughout the cytoplasm from a nucleation center in 
proximity to the nucleus. In other cells the βIII-tubulin network seemed to be more 
unorganized. Also, structures resembling the mitotic spindle were positively stained in 
dividing cells (n = 2). 
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Figure 5.2.2.4: Upper panels show confocal imaging of glioma cells lines immunostained for GFAP after 
culturing in 21 % oxygen. Lower panels show staining for GFAP in cell lines from the same cultures 
after incubation in 0.5 % oxygen for eight days. Scale bars = 20 μm, nuclear counterstaining: DAPI 
(blue), GFAP: Texas Red (red). 
 
Only one of the cell lines in our panel, U251, was positive for GFAP (figure 5.2.2.4). This 
was seen both in cells cultured in normoxia and in cells incubated in hypoxia at 0.5 % for 
eight days. The positive cells of U251 are seen as small clusters that stained positive for 
GFAP. The other cell lines were negative for GFAP both when maintained in normoxia and 
after incubation in hypoxia for eight days (n = 2). 
 
Overall, when cell line markers were investigated by ICC, there was no marked difference 
between cells cultured under normoxia or hypoxia. We also assessed expression in glioma 
cells cultured in 2 % oxygen and at day four, twelve and after five weeks but found no 
consistent changes (data not shown). This applied to all four cell line markers and in all five 
cell lines investigated.  
 
5.3 Cell proliferation, cell death and cell migration of glioma cell 
lines  
5.3.1 Growth curves for three glioma cell lines in normoxia and hypoxia 
To investigate the proliferation of cells incubated in hypoxia at 0.5 % oxygen compared to 
normoxia, growth curves were made for the cell lines LN18, U87 and U251. 10.000 cells 
were seeded in each of six cell flasks on day 0, three flasks were incubated in normoxia and 
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three in hypoxia at 0.5 % oxygen. Counting was performed on day three, six and nine. The 
experiment was repeated two times for each cell line (n = 3). 
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Figure 5.3.1: Growth curves for the cell lines LN18 (A), U87 (B) and U251 (C) in 
normoxia (N) and hypoxia (H) at 0.5 % oxygen. The x-axis indicates the days when 
counting was done and the y-axis indicates the number of cells that were counted in 
each flask. Error bars represent SEM. 
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It is evident from figure 5.3.1 A, B and C that cell numbers were increasing with a higher rate 
in normoxia, this is especially clear at day nine and the trend applies to all three cell lines. The 
difference in cell numbers at each time point is not statistically significant (p = 0.33, p = 0.23, 
p = 0.16, respectively for cell line LN18, U87 and U251 at day nine). 
  
5.3.2 BrdU pulsing of normoxic and hypoxic cells 
BrdU is a thymidine analogue, and is therefore incorporated into DNA during the S-phase of 
the cell cycle. By pulsing cells with BrdU for a short time (45 minutes) before fixation, and 
then perform ICC with an antibody directed against BrdU, we could identify all cells that had 
been in the S-phase in the period before fixation. BrdU pulsing was done in order to 
investigate the number of cells going through the S-phase at each time point when cultured in 
normoxia and incubated in hypoxia (figure 5.3.2). Hypoxia reduced the percentage of BrdU-
positive cells (25.5 %) compared to normoxia (38.2 %, p = 0,025, n = 2).  
 
Figure 5.3.2: Confocal images of immunostaining for BrdU in the cell line LN18 
cultured for a few passages in normoxia (left panel), and after culturing in hypoxia at 
0.5 % oxygen for nine days (right panel). The number of green nuclei, indicating BrdU 
incorporation, was counted under the microscope and the BrdU-positive nuclei were 
displayed as a percentage of the total number of nuclei stained. Scale bars = 20 nm, 
nuclear counterstaining: DAPI (blue), BrdU: FITC (green). 
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5.3.3 Flow cytometric DNA analysis of normoxic and hypoxic cells  
Cell cycle distribution was analyzed in the cell line LN18 after incubation in normoxia and in 
hypoxia at 0.5 % oxygen for three days (n = 2).  
 
Figure 5.3.3: DNA analysis of the cell line LN18 incubated in normoxia (left panel) and in hypoxia 
(right panel) at 0.5 % oxygen for three days. DNA analysis was performed after three days incubation 
in both oxygen conditions. Nuclei were stained with propidium iodide (PI). 
 
Table 5.3.3: Distribution of cells in the different phases of the cell cycle when cultured in normoxia and 
in hypoxia at 0.5 % oxygen for three days. 
Phase Normoxia Hypoxia 
G1 53.33 % 67.61 % 
S 26.06 % 18.56 % 
G2/M 10.53 % 11.43 % 
 
In the sample cultured in normoxia, 53.33 % of the cells were in the G1-phase, 26.06 % were 
S-phase cells and 10.53 % were in the G2/M-phase. The sample from three days incubation in 
hypoxia had 67.61 % G1 cells, 18.56 % S-phase cells and 11.43 % of the cells were in the 
G2/M-phase (figure and table 5.3.3). Hence there were more cells in the S-phase after three 
days incubation in normoxia than after three days incubation in hypoxia, confirmed by 
correspondingly fewer cells in the G1 phase in normoxia than in hypoxia. No aneuploidity was 
detected in the samples (n = 2).  
 
Results 
54 
5.3.4 Apoptosis assay with normoxic and hypoxic cells 
We used FITC-conjugated Annexin-V, a human anticoagulant with high affinity for 
apoptosis-associated PS, to asses the fraction of apoptotic cells by flow cytometry. PI was 
used to distinguish early apoptotic cells from late apoptotic and necrotic cells (n = 2). 
 
Figure 5.3.4: Dot plots representation of the LN18 cell line when cultured in normoxia (A) and after 
incubation in hypoxia at 0.5 % for three days (B). Viable cells stayed unstained and are seen in the 
lower left quadrant. FITC-conjugated Annexin-V (FL-1) was used to detect apoptotic cells, which are 
seen as a population in the lower right quadrant. PI (FL-3) was used to separate late apoptotic/necrotic 
cells, which are seen as the population in the upper right quadrant.  
 
Table 5.3.4: The percentage of cells comprising the three different populations of live, apoptotic and 
late apoptotic/necrotic cells when cultured in normoxia and in hypoxia at 0.5 % oxygen for three days. 
Condition Normoxia Hypoxia 
Live 90.0 % 84.4 % 
Apoptotic 2.7 % 7.4 % 
Late apoptotic/necrotic 5.9 % 7.2 % 
 
The percentage of apoptotic cells was higher after three days in hypoxia (7.4 %) than in 
normoxia (2.7 %, figure and table 5.3.4). Late apoptosis or necrosis was also slightly higher in 
hypoxia, with 7.2 % of cells compared to 5.9 % late apoptotic or necrotic cells in normoxia. 
The size of the viable cell populations (84.4 % in hypoxia and 90 % in normoxia) 
supplemented the numbers of apoptotic and necrotic cells. Furthermore, microscopy prior to 
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Annexin-V staining showed higher cell numbers in the normoxic compared to the hypoxic 
samples. 
 
5.3.5 Glioma cell lines migrate slower when cultured in 0.5 % oxygen 
Since several studies previously have shown that hypoxia may promote tumor invasion and 
glioma cell invasion, we wanted to study the effect of various oxygen concentrations in our 
panel of glioma lines. Thus, we used a wound healing assay combined with ECIS-monitoring 
to assess cell migration. 
 
Figure 5.3.5: The ECIS graphs show wounding and subsequent migration of U251 cells cultured in 
normoxia (left panel) and in hypoxia at 0.5 % oxygen (right panel). The x-axis indicates hours and the y-
axis the impedance. The red arrow indicates the time of wounding. 
 
Increasing impedance at the beginning of the experiment showed a rising number of cells 
growing on the electrode (figure 5.3.5). When confluent, wounding/killing of the cells was 
performed, as seen as the sudden drop in impedance. Then the time was measured until the 
impedance was back at the same level as directly before wounding. The experiment was 
performed with the cell line U251 in normoxia (n = 5) and in hypoxia (n = 8) at 0.5 % 
oxygen. The average time it took for the cells to migrate back onto the electrode was 
measured to 9.1 hours for cells in normoxia and 15.9 hours for cells in hypoxia (p = 0.0096). 
Thus, cell migration properties seem to be impaired in cells cultured in hypoxia at 0.5 % when 
comparing to normoxic cells.  
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6 Discussion 
Hypoxia contributes to the cellular environment both in normal development and disease, and 
the cellular adaption to hypoxia is accompanied by extensive changes in cell behavior. In 
cancer, hypoxia triggers angiogenesis, promotes tumor cell invasion and mediates resistance 
to both chemo- and radiotherapy. Collectively, these data suggest that hypoxia increases 
tumor aggressiveness and is associated with a poor prognosis.  
 
In recent years, cancer stem cells have been isolated from various solid tumors, including 
glioblastoma multiforme
90, 91
. CSCs have been linked to treatment resistance similar to 
hypoxia. Thus, it is conceivable that the effect of hypoxia is mediated through its effects on 
the CSC pool. Recently, several studies have reported hypoxia-induced expression of stem 
cell markers together with higher clonogenic and proliferative properties and less apoptosis in 
hypoxia
56, 66, 88, 90
. In contrast, others has shown that proliferation cease in hypoxia
88
.  
 
Currently, both primary tumor tissue directly from the patient and in vitro propagated cancer 
cell lines are frequently used in experimental studies. Whereas primary tumor tissue mimics 
the tumor in situ more closely, the limited availability of such tissue has restricted their use. 
Moreover, the extensive cellular heterogeneity within primary tissue represents a challenge, 
and not all patient biopsies can be propagated in vitro. In contrast, experiments using cancer 
cell lines can be easily standardized, although their relevance to human tumors can be 
compromised through prolonged culturing in vitro
77
. However, these cell lines are in 
widespread use, which allows for comparison of data obtained in different labs. Thus, we 
investigated the response to hypoxia in a panel of five commonly used human glioma cell 
lines (cultured in serum containing medium) by assessing their expression of cell line markers 
as well as growth rates and migratory capacity in normoxia and hypoxia.  
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6.1 Response to hypoxia 
6.1.1 HIF-1α is stabilized and translocated in hypoxia conditioned glioma 
cell lines 
We confirmed stabilization and nuclear translocation of HIF-1α after incubation in hypoxia at 
0.5 % for 24 hours. This was as expected since HIF-1α is known to become rapidly degraded 
under normoxic conditions, while the lack of oxygen inhibits its breakdown
25
. Additionally, 
cells incubated in hypoxia at 2 % oxygen showed staining for HIF-1α, albeit slightly weaker. 
Thus, it is apparent that there is a response to hypoxia in the cells, both in 2 % and 0.5 % 
oxygen, and that the effect of oxygen levels on the nuclear abundance of HIF-1α is dependent 
on the degree of hypoxia. 
 
HIF-1α was investigated after five weeks incubation in hypoxia at 0.5 % as well as after 24 
hours. After five weeks HIF-1α was not detectable any longer. As Nordgren and Tavassoli 
reviews, one of the HIF-3α isoforms, inhibitory PAS domain protein (IPAS) seems to be a 
downstream target of HIF-1α. Thus IPAS is upregulated in hypoxia creating a negative 
feedback loop for regulation of HIF-1α. This is proposed to provide the cell with a defense 
mechanism against activation of HIF-1α for a prolonged time76, and might explain the 
absence of HIF-1α after five weeks seen in our experiments. Also, there is a possibility that 
other transcription factors take over the function of HIF-1α during prolonged hypoxia. For 
example, Seidel et al demonstrated that HIF-2α was upregulated upon HIF-1α knockdown in 
a primary GBM cell line cultured at 1 % oxygen
66
. It is therefore possible that downregulation 
of HIF-1α during prolonged hypoxia was accompanied by upregulation of HIF-2α in our 
experiments as well. Other groups report normoxic HIF-1α activity in cell lines such as 
U87
92
, which we could not detect in the present study. This may be due to the fact that many 
different studies are performed on variants of the commercial cell lines available today. These 
variants have arisen as many cell lines have been cultured extensively in different labs for 
several decades. 
 
One could observe variations between the five cell lines in the panel concerning protein levels 
of hypoxia-induced HIF-1α. These cell lines were initially isolated from different 
glioblastomas which are tumors that display high levels heterogeneity. Internal differences 
among these cell lines might therefore reflect this heterogeneity in the original tumor, further 
exemplified by their diversity regarding traits such as morphology and proliferation rates in 
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vitro. Notably, such variations in HIF-1α levels are also seen when primary cell lines 
established from different GBM patients are cultured in 1 % oxygen
85
. If similar variations 
occur in GBMs in situ, this may be one factor underlying the variable response to radiation 
treatment among GBM patients. 
 
6.1.2 Glioma cell lines express CAIX to varying extent when cultured in 
hypoxia 
Although CAIX was uniformly upregulated in response to hypoxia, changes in expression 
levels were not significant for any of the cell lines. CAIX expression levels increased 
markedly in the cell lines A172, U118 and U251, whereas LN18 and U87 showed a smaller 
upregulation in CAIX expression. In addition to a high degree of variance between the three 
samples of RNA isolated, the lack of induced CAIX expression might be due to several other 
factors. One possible explanation is that HIF-1α is the only transcription factor known to 
regulate CAIX
76
, and HIF-2α is proposed to replace HIF-1α as the active hypoxia inducible 
factor during prolonged (> 72 hrs) hypoxia
93
. Relatively low levels of CAIX in two cell lines 
after eight days incubation in hypoxia at 0.5 % oxygen might therefore be explained by absent 
HIF-1α in the nucleus. These findings are in agreement with the lack of HIF-1α after four 
weeks incubation in hypoxia at 0.5 % oxygen. Additionally, Said et al (2008) also reported 
that CAIX is differentially induced by hypoxia in four different glioma cell lines
92
.  
 
6.2 Expression of cell line markers in hypoxia 
6.2.1 Expression of the stem cell markers CD133 and Nestin is not 
increased in hypoxia conditioned glioma cell lines 
The surface protein CD133 has long been considered as the principal stem cell marker, and is 
expressed in precursor cells of many tissues in the body as well as in different cancer types
84
. 
Several studies recent years also report an upregulation of CD133 in glioma cells derived 
from patients when cultured in hypoxia, suggesting that hypoxia induces stemness
85
. Nestin is 
an intermediate filament expressed in neural stem cells during development and is later 
replaced by GFAP in mature astrocytes and with neurofilaments in neurons. Nestin is also 
found to be re-expressed in reactive astrocytes and connected to re-entry into the cell cycle. 
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Therefore, Nestin is similar to CD133, associated with immatureness and stem cell features
86
. 
We therefore investigated these two stem cell markers to asses whether hypoxia could induce 
stemness in glioma cell lines. 
 
None of the investigated glioma cell lines did reveal any expression of CD133 neither when 
cultured in normoxia nor when incubated for eight days at 0.5 % oxygen. This contradict to 
some extent previous studies done on biopsy material
85, 88, 90
 and on some of the same glioma 
cell lines as in our panel
88, 95
. These studies report increased expression of such stem cell 
markers such as CD133 and Nestin under hypoxia. However these experiments were carried 
out using serum-free medium which reportedly favors the expansion of stem cell like cells. 
Our cell lines have been adapted to serum-containing medium through numerous passages 
according to the commercial provider ATTC. Thus we chose to keep culture conditions 
constant to allow for comparisons with data on these cell lines published by other groups. In 
addition we have previously shown that several of these cell lines did not express CD133 
when cultured in stem cell medium
96
. However, even if some glioma cell lines have the 
ability to re-express CD133, we can conclude that hypoxia is not enough for induction of 
CD133 expression in serum-containing medium.  
 
All five cell lines in the panel used in this study display clear expression of Nestin also in 
hypoxia, although qRT-PCR shows a downregulation of mRNA synthesis compared to 
normoxic levels. LN18 is the only cell line with clear nuclear staining of Nestin. The same 
phenomenon has been reported by other groups
97
, although the function of Nestin in the 
nucleus is not known. Glial tumors and glioma cell lines are known to express Nestin. 
Moreover, contrary to our findings Kolenda et al has shown that Nestin is upregulated in 
hypoxia in the cell line U87, although they also report expression in normoxia
88
. Notably, the 
study of Kolenda et al was also performed in serum free medium. Instead, downregulation of 
Nestin in our experiments emphasized the trend observed also in our functional studies, 
suggesting an overall slowdown of cellular processes under hypoxia. As such, these findings 
do not point to any dedifferentiation of glioma cell lines in hypoxia, like others have 
reported
56, 66, 88, 90
. 
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6.2.2 Glioma cell lines downregulate cell lineage markers βIII-tubulin and 
GFAP in hypoxia 
ICC did not reveal any clear differences in expressions of βIII-tubulin or GFAP when 
comparing cells maintained in normoxic conditions and in hypoxia at 0.5 % oxygen for eight 
days. However, qRT-PCR demonstrated a downregulation of these markers in hypoxia.  
 
βIII-tubulin is primarily used as a neuronal marker, and is not normally expressed in 
astrocytes
87
. (Therefore, Katsetos et al (2001) proposed that βIII-tubulin expression in 
astrocytic tumors to be a marker of less differentiated, highly proliferative cells associated 
with high tumor grade
87
. Particularly, Katsetos et al found βIII-tubulin positive cells in 
astrocytomas to be co-localized with strong staining of the proliferation marker Ki-67
87
. 
Expression of βIII-tubulin in GBMs and other astrocytomas is therefore a trait of transformed 
cells and may represent dedifferentiation, which is associated with CSCs. Moreover, Katsetos 
et al (2009) report increased expression of βIII-tubulin in the areas adjacent to 
pseudopalisading necrosis in GBMs
83
, connecting βIII-tubulin to hypoxia. They postulate that 
βIII-tubulin is implicated in adaptation to oxidative stress and glucose deprivation, a hallmark 
of the hypoxic environment.) The downregulation of βIII-tubulin in hypoxia which was seen 
in our experiment does not support this hypothesis.  
 
GFAP is an intermediate filament expressed in mature astrocytes
88
. U251 was the only cell 
line expressing GFAP, and in this cell line only small cell clusters were positive. It has 
previously been documented that GFAP becomes downregulated in conventional GBM cell 
lines and in glioblastoma biopsies cultured over time
89
, and the low expression of GFAP is 
therefore expected. As for the other cell line markers, expression of GFAP in U251 was 
downregulated in hypoxia.  
 
In addition, there was a considerable variation between the different cell lines in the 
magnitude with which the different cell line markers were downregulated under hypoxia. Like 
for HIF-1α and CAIX expression, this may arise because these cell lines are isolated from 
different tumors.  
 
Furthermore, it is known that under hypoxic conditions, cells decrease their overall RNA 
synthesis by 50-70 %
31
. Accordingly, the observed decline in expression of cell line markers 
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likely results from a general reduction in RNA synthesis. Especially this would seem 
reasonable for proteins that are not vital to cell survival, but whose expression may result 
from deregulated gene expression in cancer cells. An overall downregulation of the cellular 
machinery is also in correspondence with the other findings in our work; less proliferation and 
slower migration.  
 
6.3 Proliferation and apoptosis in hypoxia conditioned glioma cell 
lines 
6.3.1 Proliferation of glioma cell lines cease in hypoxia 
All cell lines examined uniformly displayed reduced growth rates in hypoxia at 0.5 % oxygen. 
Still, at each time point there is a high standard error of the mean for the three repeats in the 
experiment, which can explain why these findings were not significant. This variation may be 
due to an inaccuracy in the counting and seeding methods that may result in initial cell 
numbers deviating from 10,000. Even though there was a great variation between each 
repetition, each repeat itself clearly displayed the same biological trend with fewer cells at day 
nine in hypoxia than in normoxia. This is further underlined by examination of BrdU 
incorporation and DNA analysis of LN18 cells maintained in normoxia and LN18 cells 
incubated in hypoxia at 0.5 % oxygen. The number of BrdU positive cells was significantly 
higher in normoxia than after nine days in hypoxia, demonstrating more proliferating cells in 
normoxia. Also, the DNA analysis revealed elevated S-phase cell numbers in normoxia 
compared to cells incubated for three days in hypoxia. This is in agreement with previous 
findings that hypoxia induces arrest in the G1-phase of the cell cycle, both in a HIF-1α 
dependent and independent manner
98, 99
.  
 
As mentioned above, Nestin and βIII-tubulin are associated with the ability of rapid 
proliferation. Downregulation of these two markers in hypoxia could therefore mirror the 
cease in proliferation that we see from the growth curves. Kolenda et al (2010) shows the 
same trend; spheroid size and number as well as Ki-67 staining were negatively influenced by 
hypoxia compared to normoxia. On the other hand they found an upregulation of stem cell 
markers in hypoxia, contradictory to what we found
56, 88
. While some groups report inhibited 
growth in hypoxia
88, 100
, there are others that report that hypoxia promotes better growth with 
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higher sphere forming abilities
85
. Notably, these experiments were performed in serum free 
medium. 
 
6.3.2 Hypoxia induces apoptosis in glioma cell lines 
Flow cytometry showed a moderately but significantly increased percentage of apoptotic and 
late apoptotic/necrotic cells after incubating LN18 in hypoxia at 0.5 % oxygen for three days, 
compared to normoxia. Furthermore, FCM revealed an accumulation in the G1-phase, 
probably due to G0/G1 check point activation. Schmaltz et al (1998) reported that when 
transformed rat embryo fibroblasts were grown in hypoxia, apoptosis was not triggered unless 
the cultures experienced acidosis. Also, non-transformed cells were arrested in a G0/G1 check 
point in hypoxia
24
. Since our glioma cell culture experienced G1-arrest under hypoxia, the 
resulting cell numbers may have been too low to create an acidic environment despite 
hypoxia-induced glycolysis. Accordingly, this may have had a protective effect against 
apoptosis. In contrast to what we see, Schmaltz et al report overriding of the G0/G1 check 
point of transformed cells in non-acidic hypoxia, followed by higher proliferative abilities of 
cells in hypoxia than in normoxia
24
. However, different cell types were used in these studies, 
and may explain discrepancies between their and our findings.  
 
6.4 Migratory abilities of hypoxia conditioned glioma cell lines are 
impaired in hypoxia 
Wound healing performed in normoxia and hypoxia showed that cells migrate back into the 
wounded area faster in standard conditions than when the same experiment is done in hypoxia 
at 0.5 % oxygen. Contrary to this, several findings report an increased ability to migrate under 
hypoxic conditions, as described by Zagzag et al. Zagzag showed that two glioma cell lines 
increase migration when cultured in 1% oxygen. Several mechanisms such as downregulation 
of E- and N-cadherins in hypoxia
100
, increased signaling through the Akt pathway
101
, and 
upregulation of the chemokine receptor CXCR4 by HIF-1α102 have been proposed to 
increased migration and invasion. Taken together, the findings that cells migrate slower are 
therefore contrary to expectations. However, impaired migratory abilities may reflect the 
general slow down in cellular processes seen by cell cycle arrest and downregulation of gene 
transcription. The use of biopsy material and/or serum free medium in other studies might 
contribute to the diverging results between those and the present investigation. 
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6.5 Conclusion 
In this work, we investigated the impact of hypoxia on the expression of cell line markers and 
cell behavior in a panel of human glioma cell lines.  
 
We demonstrated stabilization of the transcription factor HIF-1a and induction of its 
downstream target CAIX, confirming that our model sufficiently mimicked the hypoxic niche 
in tumors in situ. 
 
Nestin and βIII-tubulin were both extensively expressed in all glioma cell lines tested. GFAP 
was only expressed in a minor part of U251 cells and CD133 was not expressed in any of the 
cell lines neither in normoxia nor hypoxia. All markers that were expressed in standard tissue 
culture conditions at 21 % oxygen were also expressed after up to five weeks in hypoxia at 
0.5 %, although they were all downregulated as assessed by q-RT-PCR.  
 
Growth curves, BrdU labeling and FCM all showed decreased growth under hypoxia. 
Furthermore, FCM demonstrated that hypoxia was associated with an accumulation of cells in 
the G1 phase and more cells undergoing apoptosis under hypoxia.  
 
In addition, ECIS experiments showed slower glioma cell migration in hypoxia compared to 
normoxia.  
 
Based on the above findings, we conclude that a stem like phenotype is not induced in 
hypoxia conditioned glioma cell lines. Furthermore, these findings are at odds with what have 
previously been reported by other groups. 
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7. Future perspectives 
Several studies, including our work, have presented conflicting results regarding the effect of 
hypoxia on stem like properties in brain tumors. I therefore believe that future studies should 
address these controversies. The present study was conducted on conventional glioma cell 
lines cultured in serum-containing medium. Studies addressing stemness in CNS-tumors have 
generally been performed in serum-free medium, the type of medium reportedly maintaining 
stem cells. Moreover, in each study only a few specimens from surgical resections have been 
examined. This study should therefore be expanded to include parallel experiments on 
conventional glioma cell lines in serum-free medium. Additionally, the study should comprise 
experiments performed on a larger selection of biopsy material derived from GBM patients to 
evaluate the effect of hypoxia on the expression of stem cell markers and cell behavior.  
 
Furthermore, little is known about the effect of hypoxia on the tumor stroma. However, it has 
become increasingly clear that tumor-stroma interactions play a major role in malignant 
disease. Future studies should therefore also characterize how the stromal cell compartment in 
tumors is affected by hypoxia. 
 
Our lab has recently established a DsRed-expressing NOD/Scid mouse in which human 
tumors can be xenografted. The resulting tumors contain human tumor cells embedded in red 
fluorescent stromal mouse cells, which allows for fluorescence-based separation of the tumor 
and stromal cell compartments. Therefore, these animal models may be a valuable tool for 
investigating the effect of hypoxia on the tumor stroma. 
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